Qualifying Therapeutic Discovery Project Grants for the State of California
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| 3-V BIOSCIENCES INC | BROAD SPECTRUM HOST FACTOR DIRECTED ANTIVIRAL THERAPEUTIC | $ 244,479.24 | |
| 5iSciences, Inc. | Application of continous negative external pressure (cNEP) to the upper airway | $ 22,834.35 | $ 141,124.00 |
| A.P. Pharma, Inc | APF530- Prevention of Chemotherapy-induced Nausea and Vomiting | $ 244,479.25 | |
| Aaken Laboratories | Guided Electrical Stimulation | $ 49,026.40 | $ 36,267.00 |
| Aardvark Medical, Inc. | Nasal Irrigation/Aspiration System | $ 244,479.24 | |
| Ablation Numerics Inc | Rapid and Simple Cure for Atrial Fibrillation | $ 500.00 | $ 243,979.25 |
| Acadia Pharmaceuticals Inc. | Pimavanserin | $ 244,479.25 | |
| Acaduceus Pharmaceutics Inc | Developing Novel Platinum based Targeted-Nanoparticles for Anti-Cancer Drugs | $ 12,400.00 | $ 132,500.00 |
| Acaduceus Pharmeceutics Inc | Developing Targeted Probe for PET imaging of Primary and Metastatic Melanoma | $ 56,150.00 | $ 180,000.00 |
| Accelalox Inc. | Acceleration of Bone Fracture Healing | $ 54,062.50 | $ 132,430.00 |
| Access Scientific Inc | The Wand | $ 244,479.25 | |
| Accumetrics, Inc | Gravitas: Gauging Responsiveness With a VerifyNow Assay-impact on Thrombosis & Safety | $ 244,479.25 | |
| ACEA Biosciences Inc. | Development of and cancer treatment with Bis(4-fluorobenzyl)trisulfide (BFBTS) | $ 244,479.25 | |
| AcelRx Pharmaceuticals, Inc | Sufentanil NanoTab ™ Patient Controlled Anagesia (PCA) System | $ 244,479.25 | |
| AcelRx Pharmaceuticals, Inc. | Triazolam/Sufentanil NanoTab ™ | $ 244,479.24 | |
| Achaogen, Inc | ACHN-490 - A Novel Second-Generation Aminoglycoside Antibiotic for the Treatment of Resistant Bacterial Infections | $ 244,479.25 | |
| Achaogen, Inc | Novel Expanded-Spectrum Aminoglycosides (ES-AGs) for the Treatment of Pan-Resistant Bacterial Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii | $ 244,479.25 | |
| Achaogen, Inc | Discovery and Development of a Novel Class of Antibacterials, LpxC Inhibitors for the Treatment of Multi-Drug Resistant Bacterial Infections Caused by Gram-Negative Bacteria | $ 244,479.25 | |
| Achaogen, Inc. | Discovery & Development of a Novel Orally Bioavailable Beta-Lactam for the Treatment of MRSA and Other Multi-Drug resistant Bacterial Infections | $ 244,479.24 | |
| Acologix Inc | AC 100 | $ 88,245.46 | |
| Acologix, Inc. | AC820 | $ 244,479.25 | |
| Acologix, Inc. | AC 200 | $ 170,732.65 | |
| Acorn Biomedical Inc | T-Fusion ™ Platform for oral Delivery of Recombinant Proteins | $ 125,005.10 | $ 119,474.15 |
| Acorn Biomedical Inc | Development of Adenosine A3 Receptor Antagoinst for the Treatment of Glaucoma. | $ 172,773.37 | $ 71,705.88 |
| Act Biotech , Inc | Telatinib is a new cancer drug that can readily combine with chemotherapy. | $ 244,479.25 | |
| ACT Biotech Inc | ACTB1003 a novel anti-cancer drug for treatment of cancers with FGFR gene alterations | $ 244,479.25 | |
| Active Life Scientific, Inc. | Early Diagnosis of Osteoporosis | $ 82,273.03 | $ 162,206.22 |
| ActiveSite Pharmaceuticals, Inc | Preclinical & Early Clinical Development of a NCE Targeting Diabetic Macular Edema | $ 136,104.50 | $ 108,374.74 |
| A-Cube Inc | Bi-specific c-Mat anitbodies to treat abnormal angiogensis in eye disease and cancer | $ 244,479.25 | |
| AcuFocus, Inc. | ACI 7000PDT | $ 244,479.25 | |
| Adamas Pharmaceuticals, Inc. | Once-daily Fixed Dose Combination (FDC) for Moderate-Severe Dementia Alzheimer's Type | $ 244,479.25 | |
| Adamas Pharmaceuticals, Inc. | Triple Combination Antiviral Drug Therapy for the Treatment of Infulenza | $ 244,479.25 | |
| Adamas Pharmaceuticals, Inc. | Extended-Release Amantadine for Treatment of Levodopa-induced Dyskinesia in Parkinson's | $ 244,479.25 | |
| Aduro BioTech | Thermotherapy for the treatment of Cancer | $ 197,978.50 | |
| Aduro BioTech | Listeria-Based Immunotherapy for Cancer and Infectious Disease | $ 235,971.50 | $ 8,507.75 |
| Advanced Bifurcation Systems | Advanced Bifurcation Systems Platform for Complete Bifurcation and Side Branch Stenting | $ 150,636.50 | $ 93,842.75 |
| Advanced Cell Diagnostics, Inc | Diagnostic tests based on in situ RNA detection for personalized cancer management | $ 244,479.25 | |
| Advanced Cell Technology Inc | Pluripotent Stem Cell Therapy for the Treatment of Stargardt's Macular Dystrophy | $ 244,479.25 | |
| Advanced Cell Technology, Inc. | Autologous Skeletal Myoblast Transplantation to Treat Ischemic Cardiomyopathy | $ 244,479.25 | |
| Advanced Cell Technology, Inc. | Generation of Pluripotent Embryonic Stem Cells without Destruction of Donor Embryo | $ 244,479.25 | |
| Advanced Cell Technology, Inc. | Inducing Pluripotency fron Differentiated Somatic Cells for Autologus Stem Cell Therapy | $ 244,479.25 | |
| Advanced Genetic Systems | Development of a Novel RNA-protein Complex Inhibitor for Treatment of HIV | $ 117,108.50 | $ 127,370.75 |
| Advanced Targeting Systems Inc | A Novel Cancer Pain Therapeutic | $ 19,705.50 | $ 21,576.50 |
| Advantageous Systems, LLC | ADS-NPTMZ-1, A Novel Nanotherapeutic for Selective Treatment of Advanced Melanoma | $ 27,428.00 | $ 63,714.00 |
| Adventrx Pharmaceuticals, Inc | ANX-530 | $ 244,479.25 | |
| ADVENTRX Pharmaceuticals, Inc. | ANX-514 | $ 244,479.25 | |
| AEGEA Medical Incorporation | endometrial ablation | $ 244,479.25 | |
| Aeolus Pharmaceuticals, Inc. | Development of AEOL11207 as a treatment for Parkinson's disease | $ 92,406.00 | |
| Aeolus Pharmaceuticals, Inc. | Development of AEOL10150 as a treatment for ARS/DEARE | $ 244,479.25 | |
| Aespis Biopharmaceutical Company | A Novel Cancer Therapeutic | $ 244,479.25 | |
| Afferent Pharmaceuticals, Inc | Development of a Novel Pharmaceutical, AF-219 | $ 244,479.25 | |
| Affinity Pharmaceuticals | Tumor microenvironment activated prodrug | $ 244,479.25 | |
| Affinity Pharmaceuticals | PET imaging agents of tumor microenvironment | $ 244,479.25 | |
| Affymax, Inc. | Peginesatide | $ 244,479.25 | |
| Afraxis, Inc | Afraxis PAK inhibitor project | $ 244,479.24 | |
| Aires Pharmaceuticals Inc | Development of Aironite to Treat Pulmonary Arterial Hypertension | $ 244,479.24 | |
| Aleeva Medical Inc | Alleviate back pain with disc shunt | $ 21,732.00 | $ 222,747.25 |
| Alexza Pharmaceuticals, Inc. | Staccato Loxapine | $ 244,479.24 | |
| Alion Pharmaceuticals Inc | Development of a new Alzheimer's Therapeutic | $ 167,000.00 | |
| Alios BioPharma Inc | ALS-2135 Improving Nucleoside Antiviral Properties through a Novel Produg Technology | $ 244,479.24 | |
| Alios BioPharma Inc | ALS-012117 - A Broad-Spectrum Antiviral that Activates the RNase L Pathway | $ 244,479.25 | |
| Alios BioPharma, Inc | ALS-2160 - Novel Sugar Substituted Nucleoside for the Treatment of Chronic Hepatitis C | $ 244,479.24 | |
| Alios BioPharma, Inc | Glycoferon- A Hyperglycosylated interferon with Improved Pharmacokinetitc Properties | $ 244,479.24 | |
| Allele Biotechnology & Pharmaceuticals Inc | DNA Ratio Change Technology for Prenatal Diagnosis | $ 12,458.50 | $ 232,020.75 |
| Allele Biotechnology & Pharmaceuticals Inc | STEAP4 as a Target for Obesity and Diabetes Therapy | $ 17,799.00 | $ 24,170.00 |
| Allele Biotechnology & Pharmaceutics, Inc | Use of UV-Absorbing Biological products for Skin Protection | $ 26,168.50 | $ 51,717.00 |
| Allon Therapeutics Inc | Davunetide for the treatment of PSP | $ 244,479.24 | |
| Allon Therapeutics, Inc. | AL-309 for the treatment of peripheral neuropathy | $ 137,166.50 | $ 107,312.74 |
| Allvivo Vascular, Inc. | Dual Function Antimicrobial Catheter | $ 142,899.52 | $ 101,579.73 |
| ALPHA ORTHOPAEDICS, INC | ReleF Technology | $ 59,290.00 | $ 185,189.24 |
| Alpha Source LLC | System for Production of Medical Radioisotopes | $ 238,271.21 | $ 6,208.03 |
| Altermune Technologies, LLC | Altermune: Chemically Programmable Immunity | $ 244,479.24 | |
| Altheos Inc. | ATS907: Development of a Novel Topical Rho Kinase Inhibitor for Treatment of Glaucoma | $ 10,689.00 | $ 233,790.24 |
| Altura Medical, Inc | Altlura Medical AAA endograft system to repair abdominal aortic aneurysms | $ 244,479.25 | |
| Alvine Pharmaceuticals Inc | ALV003 Therapeutic Development Project | $ 244,479.24 | |
| Alvine Pharmaceuticals Inc | ALV003 2nd Generation Therapeutic Development Project | $ 68,374.00 | $ 176,105.25 |
| Alvine Pharmaceuticals, Inc | Celiac Disease Biomarker development Project | $ 23,076.50 | $ 143,160.00 |
| Amaranth Medical Inc | Coronary Artery Vascular Restoration Therapy Drug Eluting Bioresorbable Stent | $ 244,479.24 | |
| Amaranth Medical, Inc | Drug Eluting Bioresorable Stent for PVD Vascular Restoration Therapy | $ 244,479.24 | |
| Ambit Biosciences Inc | AC220 (FLT3) Program | $ 244,479.24 | |
| Ambit Biosciences Inc | CSF1R/AC710 Kinase Program | $ 244,479.24 | |
| Ambit Biosciences Inc | AC480 Treatment Program | $ 244,479.24 | |
| AMBIT BIOSCIENCES, INC. | AC430 JAK2 KINASE PROGRAM | $ 244,479.24 | |
| Ambrx Inc | PEG-Leptin for the treatment of obesity and Type 1 Diabetes | $ 244,479.25 | |
| Ambrx Inc | ARX-Trail for the treatment of metastatic colon cancer | $ 217,366.50 | $ 27,112.75 |
| AMBRX, INC | ANTIHER2-DOLOSTAIN ANTIBODY ("ARX-AHD) for the treatment of breast cancer | $ 244,479.25 | |
| Ambrx, Inc | Anti-VEGF-Anti-Ang2 for the treatment of newvascular age related macular degeneration | $ 244,479.25 | |
| AMBRX, INC | ARX618(FGF21) for the treatment Type II Diabetes | $ 244,479.25 | |
| American Life Science Pharmaceuticals, Inc. | Alzheimer's Disease Cathepsin-B Inhibitor Therapeutics | $ 244,479.24 | |
| AMIRA PHARMACEUTICALS, INC | Lysophospahidic Acid Receptor Antagonist and Inhibitor (LPA) | $ 244,479.25 | |
| AMIRA PHARMACEUTICALS, INC | PROSTAGLANDIN D2 RECEPTOR ANTAGONIST (DP2) | $ 244,479.25 | |
| Amplyx Pharmaceuticals Inc | A Hybrid Therapeutic with superior Efficacy Against Resistant Infections | $ 54,626.50 | |
| Amplyx Pharmaceuticals, Inc | Novel Taxane with Greatly Reduced Peripheral Neuropathy for Cancer Therapy | $ 96,445.50 | |
| Amplyx Pharmaceuticals, Inc | A Novel Carbapenem Antibiotic to improve Therapeutic Outcomes | $ 81,777.50 | $ 83,514.50 |
| Amplyx Pharmaceuticals,Inc | Novel, Targeted HIV Protease Inhibitor to Improve Therapeutic Outcomes | $ 149,473.50 | $ 71,016.50 |
| Amunix, Inc | CANCER | $ 139,116.83 | |
| Amunix, Inc | Genetic Deficiency | $ 69,238.29 | |
| Amunix, Inc | Immune Diseases | $ 172,881.67 | |
| Anacor Pharmaceuticals, Inc | AN2898, a topical anti-inflammatory therapy for the treatment of atopic dermatitis | $ 244,479.25 | |
| Anacor Pharmaceuticals, Inc | AN5973, a novel agent for treatment of Enterobacteriaceae infections caused by Enterobacteriaceai bacteria. | $ 244,479.25 | |
| Anacor Pharmaceuticals, Inc | Novel agents to treat Community-Acquired Respiratory Tract Infections. Novel boron-containing small molecule antibacteria agents to treat community-acquired respiratory tract infections (CART1) | $ 244,479.25 | |
| Anacor Pharmaceuticals, Inc | AN2728, a novel topical anti-inflammatory therapy for psoriasis | $ 244,479.25 | |
| Anacor Pharmaceuticals, Inc | AN2690, a novel, broad spectrum antifungal therapy for onychomycosis | $ 136,082.50 | $ 108,396.75 |
| Anacor Pharmaceuticals, Inc. | AN2718, a topical antifungal therapy for tinea pedis | $ 244,479.25 | |
| Anadys Pharmaceuticals Inc | ANA598 | $ 244,479.25 | |
| Anadys Pharmaceuticals Inc | ANA773 | $ 244,479.25 | |
| Anaphore, Inc. | TL1A-Atrimer Therapeutic | $ 206,740.50 | $ 37,738.75 |
| Anaphore, Inc. | TRAIL-R-Atrimer Therapeutic | $ 244,479.25 | |
| Anaphore, Inc. | IL-23R/IL-10R-Atrimer Therapeutic | $ 244,479.25 | |
| AnaptysBio Inc | A Novel Therapeutic Antibody for the Treatment of Chronic Autoimmune Disease (ANA04) | $ 244,479.25 | |
| AnaptysBio Inc | A Novel Therapeutic Antibody for the Treatment of Bone Loss (ANA01). | $ 237,033.00 | |
| AnaptysBio Inc | A Novel Therapeutic Antibody for the Treatment of Chronic Pain (ANA01) | $ 244,479.25 | |
| AnaptysBio Inc | A Novel Therapeutic Antibody for the Treatment of Complement Mediated Diseases (ANA06) | $ 48,992.00 | $ 85,498.50 |
| AndroScience Corporation | A New Class of Anti-Androgen Targeting Androgen Receptor (AR) | $ 244,479.25 | |
| Angelica Therapeutics Inc | Nonimmunogenic Fusion Toxin Platform for Cancer Therapy | $ 244,479.25 | |
| Angstrom Pharmaceuticals, Inc | A6 a Novel CD44 Targeting Cancer Therapeutic | $ 244,479.25 | |
| ANTHERA PHARMACEUTICALS INC | A-001 | $ 244,479.25 | |
| Anthera Pharmaceuticals Inc | A-623 for Rheumatoid Athritis | $ 10,966.00 | $ 233,513.25 |
| Anthera Pharmaceuticals, Inc | A-002 | $ 244,479.25 | |
| ANTHERA PHARMACEUTICALS, INC. | A-623 | $ 10,966.00 | $ 233,513.25 |
| AntiCancer, Inc. | Targeted Tumor-Killing Bacteria | $ 87,322.16 | $ 83,804.41 |
| Apama Medical Inc | RF Project | $ 101,461.50 | $ 143,017.75 |
| Applied BioCode Inc | Barcoded Magnetic Beads (BMB) for Molecular Diagnostics | $ 244,479.25 | |
| Applied Biotechnology Institute, Inc. | An Orally Delivered Hepatitis B Vaccine | $ 123,187.50 | $ 115,568.50 |
| APT Pharmaceuticals, Inc. | Cyclosporine Inhalation Solution to prevent and treat rejection following lung transplant | $ 244,479.25 | |
| Aptus Endosystems, Inc | The Aptus Endostape in the prevention and treatment of abominal aortic aneurysms | $ 244,479.25 | |
| AqueSys Inc | Aquesys Microfistula Implant | $ 244,479.25 | |
| Ara Medical, LLC | Sprayable biodegradeable polymers as adhesion barriers & drug delivery modality | $ 183,828.00 | $ 60,651.25 |
| Aradigm Corporation | ARD-3100-Liposomal Ciprofloxacin for the treatment of Cystic Fibrosis | $ 244,479.25 | |
| ARADIGM CORPORATION | ARD-3100 -- Liposomal Ciprofloxacin for the Treatment of Non-Cf Bronchiectasis | $ 244,479.25 | |
| ARADIGM CORPORATION | ARD-3150-Liposomal Ciprofloxacin for the Treatment of Non-CF Bronchiectasis | $ 244,479.25 | |
| Aragon Pharmaceuticals, Inc | 3rd Generation Anti-Androgens | $ 244,479.25 | |
| Aragon Pharmaceuticals, Inc | ARN-509 | $ 244,479.25 | |
| Aragon Pharmaceuticals, Inc. | SERD | $ 244,479.25 | |
| Aravasc Inc | Multi-modal drug delivery system for local delivery of Cancer Chemotherapy | $ 135,274.28 | $ 109,204.97 |
| Arbor Vita Corporation | NA-1 | $ 244,479.25 | |
| Arbor Vita Corporation | AVC Avantage HPV E6 Test | $ 244,479.25 | |
| Arbor Vita Corporation | Anvantage A/H5N1 Flu Test | $ 244,479.25 | |
| Ardea Biosciences Inc | Next-generation URAT1 Therapeutic Discovery Project | $ 244,479.25 | |
| Ardea Biosciences Inc | RDEA119-MEK Inhibitor Therapeutic Discovery Project | $ 244,479.25 | |
| Ardea Biosciences Inc | RDEA594-URAT1 Therapeutics Discovery Project | $ 244,479.25 | |
| Ardelys Inc. | RDX5791 for the treatment of CIC, IBS-C predominant and OBD | $ 244,479.25 | |
| Ardelyx Inc. | RDX002 for the treatment of elevated phosphorus in chronic kidney disease | $ 244,479.25 | |
| Ardelyx, Inc | RDX008 treatment of salt and fluid overload in heart failure, CKD and hypertension patients congestive heart failure (CHF), chronic kidney disease and hypertension. | $ 119,704.00 | $ 124,775.25 |
| Argusina, Inc. | Novel Small Molecular Modulator of GLP1 Receptor for Anti-Diabetes/Obesity Treatment | $ 171,732.44 | $ 72,746.80 |
| Aridis Pharmaceuticals LLC | Aridis Formulation Technology Program | $ 244,479.25 | |
| Aridis Pharmaceuticals, LLC | Aridis Novel Anti-Infective Therapies Program | $ 244,479.25 | |
| ArKal Medical Inc | ArKal Continuous Glucose Monitor | $ 244,479.24 | |
| ArmaGen Technologies Inc | Drug Development of Brain-Penetrating Biopharmaceuticals | $ 244,479.24 | |
| Arresto Biosciences, Inc | AB0024, a Novel Inhibitor of LOXL2 for the Treatment of Cancer and Fibrotic Diseases | $ 244,479.25 | |
| Arrowhead Research Corporation | Rondel | $ 244,479.25 | |
| Arstasis, Inc. | ArtasisONE Vascular Access System | $ 244,479.25 | |
| Artemis Health, Inc. | Noninvasive Prenatal Diagnosis of Down Syndrome Using Next-Generation DNA Sequencing | $ 244,479.25 | |
| Artery Therapeutic, Inc | Artery Therapeutic, Inc: Diagnostic Program | $ 41,602.96 | $ 202,876.29 |
| Artery Therapeutics, Inc | Artery Therapeutic, Inc: Therapeutic Program | $ 172,743.80 | $ 71,735.45 |
| Aryx Therapeutics Inc | Tecarfarin Novel Oral Anticoagulant Therapeutic | $ 244,479.24 | |
| Aryx Therapeutics Inc | ATI-7505 for the treatment of gastrointestinal motility dysfunctions | $ 148,714.50 | $ 95,764.74 |
| ARYX THERAPEUTICS INC | Budiodarone oral therapeutic for the tratment of atrial fibrillation | $ 244,479.24 | |
| ARYX THERAPEUTICS, INC. | ATI-9242 for the treatment of schizophrenia and depression | $ 111,106.50 | $ 99,439.50 |
| Asante Solutions, Inc. | Personal Infusion System | $ 244,479.24 | |
| Asthmatx, Inc. | TREATING CHRONIC RESPIRATORY DISEASES WITH ALAIR SYSTEM | $ 244,479.25 | |
| ASTRAEA THERAPEUTICS, LLC | POLYDRUG ADDICTION TREATMENT | $ 4,682.50 | $ 93,112.00 |
| Astraea Therapeutics, LLC | Novel Therapies for Parkinsons Disease and Dyskinesia | $ 38,713.50 | |
| Astute Medical, Inc | A Novel Biomaker Panel for the Early Detection of Acute Kidney Injury | $ 244,479.24 | |
| AtheroMed, Inc. | Phoenix Atherectomy System | $ 244,479.25 | |
| aTyr Pharma Inc. | Tmax, an Innovative Biological Therapy for Thrombocytopenia | $ 244,479.24 | |
| aTyr Pharma Inc. | ATYR1920, a novel immunomodulatory agent for IBD | $ 244,479.24 | |
| Auritec Pharmaceuticals | Sustained Release Apomorphine for the Treatment of Parkinson's Disease | $ 80,827.37 | $ 46,125.17 |
| Auritec Pharmaceuticals | Intravaginal ring releasing acyclovir for the prevention of HSV transmission | $ 105,580.61 | $ 92,197.62 |
| Auritec Pharmaceuticals | Sustained Release Cyclosporine for the Prevention of Graft Rejection | $ 51,081.86 | $ 193,397.39 |
| Auritec Pharmaceuticals | Sustained Release Nevirapine for the Treatment of HIV | $ 65,989.98 | $ 14,366.85 |
| Auritec Pharmaceuticals | Sustained Release Olanzapine for the Treatment of Schizophrenia and Mania | $ 68,881.55 | |
| Auspex Pharmaceuticals, Inc. | SD-560-Deuterated pirfenidone analog for treatment of idiopathic pulmonary fibrosis | $ 239,933.37 | $ 4,545.88 |
| Automedics Medical Systems, Inc. | HepGuide Decision Support Software | $ 157,334.50 | $ 87,144.74 |
| Autonomic Technologies Inc | Delivery of Therapeutics for Migraine and Cluster Headache | $ 244,479.25 | |
| Avanir Pharmaceuticals, Inc | Zenvia | $ 244,479.25 | |
| Avantis Medical Systems | Development and Clinical Trials of the Third Eye Retroscope, a Device to Enhance Detection and Treatment of Colonic Adenomas and Prevent Colorectal Cancer | $ 244,479.25 | |
| AvidBiotics Corp | R-Type Pyocins as Novel Antibacterials | $ 244,479.24 | |
| AvidBiotics Corp | Targeted MICA Molecules to Recruit Innate Immunity Cells to Kill Specific Viruses | $ 38,082.50 | $ 82,718.00 |
| Aviir, Inc. | Aviir Blood Test for Heart Disease | $ 244,479.24 | |
| Axikin Pharmaceuticals, Inc. | Axikin Pharmaceuticals: Novel Small Molecule Therapy for Asthma | $ 244,479.25 | |
| Azee Inc. | Development of a new class of antibacterial and antiviral drugs using SMAT technology | $ 27,619.85 | $ 77,000.00 |
| Balance Therapeutics, Inc | Developing the first potential drug to treat the cognitive impairment in Down Syndrome | $ 14,389.84 | $ 230,089.41 |
| BARnova, Inc | TransPyloric Shuttle | $ 244,479.24 | |
| BaroSense Inc | Trans-oral Endoscopic Restrictive Implant System (TERIS) | $ 244,479.24 | |
| BARRX MEDICAL INC. | Albation of Squamous Neoplasia and Esophegeal Squamous Cell Carcinoma | $ 43,364.00 | $ 69,826.00 |
| BARRX MEDICAL INC. | Albation of Intestinal Metaplasia (AIM) Dysplasia Extension of follow-up to 5 years | $ 218,622.50 | $ 25,856.75 |
| BARRX MEDICAL INC. | Halo Patient Registry- Ablation of Barrett's Esophagus | $ 244,479.25 | |
| BARRX MEDICAL INC. | Micro-Layer Ablation of Barrett's Metaplasia- Extension of Follow-Up to 5 years | $ 52,077.00 | |
| Bayhill Therapeutics | BHT - 3021 | $ 244,479.25 | |
| Bayhill Therapeutics | BHT - 3034 | $ 244,479.25 | |
| Bebaas Inc | Cyprem | $ 242,500.00 | $ 1,979.25 |
| Bebaas Inc | Cobacan | $ 242,500.00 | $ 1,979.25 |
| BeneChill, Inc | RhinoChill | $ 244,479.24 | |
| Beyond Lucid Technologies, Incorporated | MEDIVIEW DX by Beyond Lucid Technologies, Inc. | $ 9,477.83 | $ 157,022.86 |
| BFIONOVO, Inc. | MENERBA | $ 244,479.25 | |
| Bio Time Inc | Induced Pluripotent Stem Cell Technologies | $ 112,580.75 | $ 131,898.50 |
| Bio3 Research Inc. | HMGB1 for accelerated wound healing | $ 20,439.00 | $ 32,032.00 |
| BioAssay Systems LLC | Development of Pharmacodynamic and Diagnostic Assays for Cancer Drug Targets | $ 244,479.24 | |
| BioAtla, LLC | Development of a High Affinity Antibody for nonHodgkin's Lymphomas | $ 28,500.00 | $ 37,350.00 |
| BioCardia, Inc | Helical Infusion System for Heart Failure | $ 244,479.25 | |
| Biocept, Inc. | CEE Cell Enrichment and Extraction Platform Technology | $ 244,479.25 | |
| Biodesy LLC | Discovery of a highly specific and potent therapeutic for Parkinson's disease | $ 71,058.50 | $ 39,996.50 |
| BioDx Partners LLC | Development and Commercialization of a Blood Test for Non-Small Cell Lung Cancer | $ 3,450.50 | $ 138,599.50 |
| Bioenergenix, LLC | BioEnergenix | $ 244,479.25 | |
| BioGenex Laboratories | Develop fully automated tools for quantitative gene expression profiling in situ for cancer. | $ 244,479.25 | |
| Biological Dynamics, Inc. | Point of Care Cancer Diagnostic Device | $ 244,479.25 | |
| Biomatrica Inc | Development of Molecular Diagnostic Tools for High-Sensitivity Cancer Detection | $ 244,479.25 | |
| BioMedicure LLC | Developing Cancer Vaccines to Prevent and Treat Cancer including Melanoma | $ 196,047.50 | $ 48,431.74 |
| Biomerica Inc | Enzyme-Linked Immunosorbent Assays (ELISA) | $ 172,890.28 | $ 71,588.97 |
| Biomerica, Inc | Microalbumin Project | $ 44,185.60 | $ 68,811.41 |
| BIONOVO, INC | BEZIELLE | $ 244,479.25 | |
| BioTechPlex Corporation | SUPRAER:High Dose-Rate Aerosol Delivery of Biotherapeutics | $ 19,271.00 | $ 36,681.50 |
| BioTime Inc | ACTCellerate Embryonic Progenitor Cells | $ 244,479.25 | |
| BioTime, Inc | Chondrocyte Progenitor Cells | $ 119,663.74 | $ 124,815.51 |
| BioVascular Inc | Anagrelide Control Release for Cardiovascular Risk Reduction | $ 244,479.24 | |
| BioVascular Inc. | Development of Saratin to increase vascular graft survival | $ 244,479.24 | |
| Bioxiness Pharmaceuticals | Development of Novel and New Class of Antimicrobial Therapeutics | $ 18,780.00 | $ 225,699.25 |
| BN Immuno Therapeutics Inc | MVA-BN-HER2 | $ 244,479.25 | |
| BN Immuno Therapeutics Inc | PROSTVAC | $ 244,479.25 | |
| BrainCells Inc | BCI-632 | $ 244,479.25 | |
| BrainCells Inc. | BCI-540 | $ 244,479.25 | |
| BrainCells Inc. | BCI-952 | $ 244,479.25 | |
| BrainCells Inc. | BCI-224 | $ 244,479.25 | |
| Broncus Technologies, Inc | LungPoint Planning and Navigation Systems | $ 244,479.25 | |
| Broncus Technologies, Inc. | Airway Bypass with Drug-Eluting Stents | $ 244,479.25 | |
| Broncus Technologies, Inc. | FleXNeedle Tissue Sampler (18 Gauge) | $ 244,479.24 | |
| Bruin Biometrics, LLC | Sub-epidermal moisture scanning device | $ 244,479.25 | |
| C2 Therapeutics, Inc | Cryoballon Ablation System for Barrett's Esophagus | $ 176,887.51 | $ 67,591.74 |
| C3 Jian, Inc. | Specifically-targeted antimicrobial peptides ("STAMPs) | $ 244,479.25 | |
| C8 MediSensors, Inc. | HG-1c Noninvasive Glucose Monitor | $ 244,479.25 | |
| Cadence Pharmaceuticals, Inc. | OFIRMEV, A NEW INTRAVENOUS TREATMENT FOR ACUTE PAIN AND FEVER | $ 244,479.25 | |
| Caerus Molecular Diagnostics Inc. | Low-Cost Diagnostic Platform using Millikan Sequencing | $ 150,000.00 | |
| CalciMedica, Inc | Novel therapies for autoimmune diseases | $ 244,479.24 | |
| Caldera Medical, Inc | POP SI | $ 117,025.76 | $ 127,453.49 |
| Caldera Medical, Inc. | Desara Mini | $ 140,691.80 | $ 103,787.44 |
| Calibra Medical, Inc. | Finesse Personal Insulin Delivery System | $ 244,479.24 | |
| Califia Bio, Inc. | Discovery of Novel Therapeutics for the Treatment of HIV-associated Neurological Disease | $ 128,113.00 | $ 116,366.25 |
| California Stem Cell Inc | MotorGraft | $ 244,479.25 | |
| Calithera Biosciences Inc | Caspase Activator Program | $ 244,479.25 | |
| Cameron Health, Inc | S-ICD System, Subcutaneous Implantable Defibrillator to Treat Sudden Cardia Death | $ 244,479.25 | |
| Cantimer Incorporated | Osmo Point-of-Care Dehydration Diagnostic System | $ 244,479.25 | |
| Capnia, Inc. | A Novel Therapeutic Product for Treating Migraine | $ 244,479.24 | |
| Capnia, Inc. | A Novel Therapeutic Product for Allergic Rhinitis | $ 244,479.24 | |
| Capnia, Inc. | A Novel Diagnostic Device for Detecting Hemolysis | $ 3,915.00 | $ 240,564.24 |
| Capricor, Inc. | Cardiosphere-derived stem cell therapy for advanced heart failure | $ 129,094.00 | $ 115,385.25 |
| Capso Vision Inc | CapsoCam Colon Capsule Endoscope | $ 244,479.25 | |
| Carbylan Biosurgery Inc. | Hydros TA | $ 244,479.25 | |
| Cardero Therapeutics, Inc | Mitochondrial Protection and Stimulation (MIPS) Drug Development Program | $ 95,437.50 | $ 149,041.75 |
| Cardigant Medical Inc | Project Nautilus | $ 60,200.00 | $ 110,550.00 |
| Cardima, Inc. | Catheter ablation technology | $ 244,479.24 | |
| CARDIODX INC | Corus SCA (sudden cardiac arrest)genetic test for the detection of cardiac arrhythmia risk | $ 244,479.24 | |
| CardioDx, Inc. | Corus CAD gene expression test for obstructive coronary disease (CAD) | $ 244,479.24 | |
| Cardiogenesis Corporation and Subsidiaries | Phoenix Project | $ 195,528.76 | $ 48,950.49 |
| Cardiovascular Simulation Inc | CT Flow: Non-Invasive Assessment of Coronary Artery Disease | $ 119,606.00 | $ 124,873.25 |
| Cardium Therapeutics, Inc. | Generx ® ("Generx") | $ 244,479.24 | |
| Carmot Therapeutics, Inc | Identification of novel anticancer drugs | $ 244,479.24 | |
| Carolus Therapeutics, Inc | Peptide Therapeutic-CT-2008 | $ 244,479.25 | |
| Catalyst Biosciences, Inc. | Improved recombinant human Factor Vlla | $ 244,479.24 | |
| Catalyst Biosciences, Inc. | Anti-complement Alterase TM therapeutic program | $ 244,479.24 | |
| Catalyst Biosciences, Inc. | Improved recombinant human Factor IX | $ 244,479.24 | |
| CEBIX Incorporated | C-Peptide Replacement Therapy | $ 244,479.24 | |
| Cell Biosciences, Inc | Nanoimmunoassay for Biomarker Detection | $ 244,479.24 | |
| Cell Viable Corp | Small Molecule to treat Neurodegenerative Disease such as Alzheimers | $ 17,250.00 | |
| Celladon Corporation | MYDICAR (AAV1/SERCA2a) for treatment of NYHA Class III/IV symptoms of heart failure | $ 244,479.24 | |
| CellScape Corporation | CellScape NIPD System | $ 244,479.24 | |
| CellSight Technologies Inc | Imaging cell trafficking to advance clinical translation of cell and gene therapeutics | $ 105,795.00 | |
| Celprogen Inc. | Therapeutic agents for the treatment of Breast Cancer triple negative patients | $ 107,500.00 | $ 136,979.24 |
| Celula Inc | High-Capacity Single-Cell Molecular Diagnostics for Non-Invasive Prenatal Genetic Testing | $ 244,479.25 | |
| Cenna Biosciences Inc | Peptide Drugs to Treat Alzheimer's Disease | $ 16,248.50 | $ 228,230.75 |
| Ceregene, Inc | Ceregene, Inc | $ 244,479.25 | |
| Ceregene, Inc | Neurotrophic Factor Therapy (AAV-NGF) for the Treatment of Alzheimer's Disease (CERE-110) | $ 244,479.25 | |
| Ceregene, Inc. | Delivery of NT-4 for the Treatment of Degenerative Ocular Diseases (CERE-140) | $ 244,479.25 | |
| Cerimon Pharmaceuticals | Diclofenac sodium topical patch for treatment of acute musculoskeletal pain | $ 244,479.24 | |
| Cerus Corporation | INTERCEPT Pathoogen Inactivation for Platelets | $ 244,479.25 | |
| Cerus Corporation | INTERCEPT Pathogen Inactivation for Red Blood Cells | $ 244,479.25 | |
| Charisela Technologies Inc | Charisela Technologies: Advanced Reagent Technologies | $ 213,581.03 | |
| CHEM DIV INC | NOVEL SMALL MOLECULE HEDGEHOG PATHWAY INHIBITORS AS ANTICANCER AGENTS | $ 73,690.00 | $ 65,481.00 |
| ChemGenex Pharmaceuticals, Inc. | Omacetaxine Mepesuccinate | $ 244,479.24 | |
| ChemoCentryx Inc | Treating Chronic Hepatitis with C0334578 | $ 244,479.25 | |
| ChemoCentryx, Inc | Treating Glioblastoma Cancers with CCX662 | $ 244,479.24 | |
| ChemoCentryx, Inc | Treating Vasculitis with CCX168 | $ 244,479.24 | |
| ChemoCentryx, Inc | Treating Rheumatoid Arthritis with CCX354 | $ 244,479.24 | |
| ChemoCentryx, Inc. | Treating Inflammatory Bowel Disease (IBD) with CCX282 | $ 244,479.25 | |
| ChemoCentryx, Inc. | Treating Type 2 Diabetes with CCX140 | $ 244,479.24 | |
| ChemoCentryx, Inc. | Treating Atopic Dermatitis with C0333158 | $ 125,808.00 | $ 118,671.25 |
| ChemoCentryx, Inc. | Treating Inflammatory Bowel Disease (IBD) with CCx025 | $ 244,479.24 | |
| ChemRegen, Inc. | New Stem Cell Therapies for Heart Disease | $ 244,479.25 | |
| CHF Technologies Inc | PliCath HF System | $ 244,479.24 | |
| ChromoLogic LLC | Occular Radiation Dosimeter (OCDOS) | $ 244,479.25 | |
| ChromoLogic LLC | Rapid brain injury dosimeter (RAPIDOS) | $ 29,394.00 | |
| ChromoLogic LLC | Amplified Refractometric interference Analysis System | $ 48,256.00 | $ 20,344.00 |
| ChromoLogic LLC | Debridement and Vitality Assessment System (DAVANIS) | $ 6,429.00 | $ 29,587.00 |
| ChromoLogic LLC | Reactie Chest Seal (ReSEAL) | $ 7,842.00 | $ 14,863.50 |
| ChromoLogic LLC | Fluid preservation system (FPS) | $ 28,191.00 | |
| ChromoLogic LLC | Label free integrated biofilm analysis (LIBA) system | $ 16,109.00 | $ 16,385.00 |
| ChromoLogic, LLC | Occular Hydration Monitor (OCHYMO) | $ 110,770.50 | $ 120,380.00 |
| Chronix Biomedical, Inc. | Apoptosis Blood DNA Test to Guide Therapeutic Decisions in Cancer Management | $ 244,479.25 | |
| Cianna Medical, Inc | SAVI Applicator System | $ 244,479.25 | |
| Claremont Biosolutions LLC | Rapid Sample Preparation and Detection of C. diff. and Other Pathogens | $ 234,671.10 | $ 9,808.15 |
| Claret Medical, Inc | Dual Filter Embolic Stroke Prevention Catheter | $ 77,166.00 | $ 154,500.00 |
| Clarity Medical Systems, Inc | Holos, a unique, high resolution, real time optical measurement technology for opthalmology | $ 192,231.50 | $ 52,247.75 |
| Clarity Medical Systems, Inc | Advanced Next Generation System for Diagnostic Ocular Imaging | $ 244,479.25 | |
| Clincial Micro Sensors, Inc | K-ras mulation cancer treatment | $ 8,188.50 | $ 236,290.75 |
| Clinical Micro Sensors Inc | AD-8 DNA System | $ 171,256.00 | $ 73,223.25 |
| Clinical Micro Sensors, Inc | Plavix Sensitivity Drug | $ 60,588.00 | $ 183,891.25 |
| Clinical Micro Sensors, Inc | Warfarin Sensitivity Test | $ 110,390.50 | $ 68,026.00 |
| Clinical Micro Sensors, Inc. | Thrombophilia Risk Test (TRT) | $ 244,479.25 | |
| Clinical Micro Sensors, Inc. | Respiratory Viral Panel (RVP) | $ 244,479.25 | |
| Clinical Micro Sensors, Inc. | Cystic Fibrosis Genotyping (CF) | $ 244,479.25 | |
| CoaguSense, Inc | CoaguSense Coagulometer Project | $ 244,479.25 | |
| CoaguSense, Inc. | Hemophilia Therapeutic Monitoring Project | $ 220,220.50 | |
| Coda Therapeutics, Inc | Nexagon ® For the Treatment of Venous Leg Ulcers | $ 244,479.25 | |
| Colby Pharmaceutical Company | Development of a New Chemical Entity Inhibiting JunD Activation of the Androgen Receptor | $ 244,479.25 | |
| Colby Pharmaceutical Company | Clinical Development of CPC-100 for Recurrent Prostrate Cancer | $ 51,500.00 | $ 192,979.25 |
| Colby Pharmaceutical Company | Androgen Receptor DNA Vaccine for Prostate Cancer Patient in Vivo Immunization | $ 244,479.25 | |
| Colby Pharmaceutical Company | Tempol-based Radioprotective Solid State Oral Drug Formation for US stockpile | $ 244,479.25 | |
| COMBIMATRIX CORPORATION | COMPREHENSIVE CANCER ARRAY, OR "CCA" | $ 244,479.24 | |
| Combimatrix Molecular Diagnostics, Inc | Array Comparative Genomic Hybridization, or "aCGH" | $ 244,479.24 | |
| CoMentis Inc | BACEi | $ 244,479.25 | |
| Complete Genomics, Inc. | Complete Human Genome Sequencing for Personal Medicine | $ 244,479.24 | |
| CONATUS PHARMACEUTICALS INC. | CTS-1027 | $ 244,479.24 | |
| CONCENTRIC MEDICAL, INC | The Trevo system provides rapid clot integration and removal in patients experiencing acute ischemic stroke. | $ 244,479.25 | |
| Conkwest Inc. | NK-92 | $ 17,594.05 | $ 179,775.00 |
| Corcept Therapeutics Incorporated | Selective GR-II Antagonist-CORT 108297- Treatment of Antipsychotic Induced Weight Gain | $ 244,479.25 | |
| Corcept Therapeutics Incorporated | CORLUX for Treatment of Endogenous Cushing's Syndrome | $ 244,479.25 | |
| Corcept Therapeutics, Incorporated | CORLUX for the treatment of Psychotic Depression | $ 244,479.25 | |
| Corium International Inc | MicroCor PTH(1-34) transdermal delivery system for osteoporosis | $ 244,479.25 | |
| Cortene Inc | Hercules | $ 244,479.24 | |
| Cortex Pharmaceuticals Inc | CX1739 A novel Ampakine Molecule for Neurologicial and Psychiatric Disorders | $ 244,479.24 | |
| Crescendo Bioscience, Inc | Vectra ™ DA (Disease Activity Test) | $ 244,479.25 | |
| Crescendo Bioscience, Inc. | Crescendo Structural Damage Test | $ 244,479.25 | |
| CRISI Medical Systems, Inc | Advanced Cardiac Life Support (ACLS) Drug Delivery System | $ 1,938.05 | $ 242,541.20 |
| Cura Medical Technologies LLC | Range Compensator and Aperture Development for Proton Beam Radiation Therapy | $ 244,479.24 | |
| CuraSeal Inc | PICS therapeutics delivery system | $ 244,479.24 | |
| Customized Therapeutics LLC | Biomarker for prediciting response to chemotherapy in prostate cance patients | $ 31,666.67 | $ 60,000.00 |
| Customized Therapeutis LLc | Biomarker for predicting respons to chemotherapy in breast cancer patients | $ 36,666.67 | $ 105,000.00 |
| Cylene Pharmaceuticals Inc | CX-7000 next generation CK2 inhibtor as a personalized anticancer agent with accompanying diagnostic kit | $ 244,479.24 | |
| Cylene Pharmaceuticals Inc | FiRST-IN-CLASS CX-6258 PAN-PIM KINASE INHIBITOR AS A PERSONALIZED ANTICANCER AGENT WITH ACCOMPANYING DIAGNOSTIC KIT | $ 244,479.24 | |
| CYLENE PHARMACEUTICALS, INC | FIRST-IN-CLASS RNA POLYMERASE I INHIBITORS AS PERSONALIZED ANTICANCER AGENTS | $ 244,479.24 | |
| Cylene Pharmaceuticals, Inc | FIRST-IN-CLASS CX-4945 INHIBITORS AS PERSONALIZED ANTICANCER AGENTS with accompanying diagnostic kit | $ 244,479.24 | |
| Cynvenio Biosystems, Inc. | Liquid Biopsy: Oncogenetic analysis of Cancerous Circulating Tumor Cells | $ 229,743.50 | $ 14,735.74 |
| CytoDesign Inc (CDI) | Homogeneous Assay Platform for Clinical Diagnostics | $ 23,288.00 | |
| CytoDesign, Inc (CDI) | Engineering Proteolytic Therapeutics for Biodefense | $ 45,637.50 | |
| CytoDesign, Inc. (CDI) | Engineering Proteolytic Therapeutics for Psoriasis | $ 80,099.00 | $ 78,151.50 |
| Cytokinetics, Inc | Cardiac Muscle Activators for Heart Failure | $ 244,479.24 | |
| Cytokinetics, Inc | Skeletal Muscle Activators | $ 244,479.24 | |
| Cytokinetics, Incorporated | Smooth Muscle Myosin Inhibitors | $ 244,479.24 | |
| CytomX Therapeutics, LLC | Armed Probodies for the Treatment of Colon and Head & Neck Cancer and GBM | $ 175,983.50 | $ 68,495.74 |
| CytomX Therapeutics, LLC | Probodies for the Treatment of Triple Negative Breast Cancer and Pancreatic Cancer | $ 171,354.00 | $ 73,125.24 |
| Cytori Therapeutics Inc | The Celution System for the delivery of adipose derived stem and regenerative cells | $ 244,479.25 | |
| CytoScale Diagnostics , LLC | New-Generation CTC Cancer Diagnostic Devices | $ 244,479.24 | |
| Cytotech Labs LLC | Cytotech Labs, Api 31510 | $ 244,479.24 | |
| CytRx Corporation | INNO-206 a prodrug of doxorubicin, which selectively becomes active in tumors. | $ 244,479.25 | |
| CytRx Corporation | Tamibarotene, a novel retinoid drug for treatment of a rare form of leukemia | $ 244,479.25 | |
| CytRx Corporation | Clinical trials with Bafetinib | $ 146,172.50 | $ 98,306.75 |
| DataPhysics Research, Inc | CaseReader: Healthcare Image Processing System | $ 173,150.00 | $ 71,329.24 |
| Dean Allgeyer, M.D | Simplified Vital Signs Acquisition for the Medical Home | $ 3,252.50 | $ 5,397.50 |
| Depomed, Inc | DM-1992 for the Treatment of Parkinson's Disease | $ 244,479.24 | |
| Depomed, Inc | Serada for the Treatment of Menopausal Hot Flashes | $ 244,479.25 | |
| DermTech International | Epidermal Genetic Information Retrieval | $ 244,479.24 | |
| Deton Corp | Cough analyzer of airborne bacteria for tuberculosis and pulmonary disease diagnosis | $ 66,463.50 | |
| Devax, Inc | Axxess Drug Eluting Bifurcation Stent | $ 244,479.24 | |
| Dfine, Inc | StabiliT therapeutic delivery system | $ 244,479.24 | |
| DNAmicroarray, Inc. | Chemically Induced Reprogrammed Human Somatic Stem Cells for Treatment of Human Medi | $ 244,479.25 | |
| DOSE Medical Corporation | DOSE Medical Drug Delivery Platform | $ 244,479.24 | |
| Duke Vascular,In. | Taheri LaDuca Endograft | $ 161,302.23 | $ 83,177.02 |
| Durect Corporation | ORADUR | $ 244,479.25 | |
| DURECT CORPORATION | POSIDUR PROGRAM | $ 244,479.25 | |
| DURECT CORPORATION | BIOBETTERS PROGRAM | $ 244,479.25 | |
| DxTerity Diagnostics Incorporated | Rapid Point of Care Genetic Testing Platform for Complex Gene Expression Assays | $ 177,025.00 | $ 67,454.24 |
| Dynavax Technologies Corporation | HEPLISAV, Hepatitis B Vaccine | $ 244,479.25 | |
| Dynavax Technologies Corporation | DV1179 for the Treatment of Systemic Lupus Erythematosis | $ 244,479.25 | |
| Dynavax Technologies Corporation | Universal Flu Vaccine N8295/llVSA | $ 244,479.25 | |
| Edison Pharmaceuticals, Inc. | EPI-743 | $ 244,479.25 | |
| Edison Pharmaceuticals, Inc. | CNTO-530 | $ 244,479.25 | |
| Eiger Biopharmaceuticals, Inc | EBP921 | $ 138,813.50 | $ 105,665.75 |
| EIGER BIOPHARMACEUTICALS, INC | CLEMIZOLE AND BACK UPS | $ 244,479.25 | |
| Elcelyx Therapeutics Inc | Targeting Gut Chemosensory Receptors to Treat Obesity and Diabetes | $ 62,465.50 | $ 182,013.75 |
| Elevation Pharmaceuticals, Inc | EP-101(LAMA) | $ 244,479.24 | |
| Elixir Medical Corporation | Drug Eluting Stent (DES) | $ 244,479.25 | |
| Elixir Medical Corporation | Fully Bioresorbable Drug Eluting Stent (BDES) | $ 244,479.25 | |
| ELIXIR MEDICAL CORPORATION | Oncology Platforms | $ 199,084.50 | $ 45,394.75 |
| Elixir Medical Corporation | Ophthalmis Drug Eluting Implants | $ 199,094.00 | $ 45,385.25 |
| Elixir Medical Corporation | Drug Eluting Stent (DES) with Bioabsorbable Coating (DESyneBD) | $ 244,479.25 | |
| Ellipse Technologies Inc | Ellipse MAGEC Technology | $ 244,479.24 | |
| Emiliem, Inc | Translational Development of a Novel mTOR Pathway inhibitor for Unmet Medical Needs | $ 244,479.25 | |
| EMKinetics Inc. | An Electromagnetic neurostimulator for treatment of overactive bladder (OAB) | $ 244,479.25 | |
| EndogenX Inc. | Endothelin Antagonist in Non-Opiate Analgesia | $ 52,778.00 | $ 191,701.25 |
| ENDOLOGIX, INC. | PEVAR | $ 58,092.00 | $ 186,387.25 |
| Endoscopic Technologies, Inc DBA Estech | Treatment of Atrial Fibrillation Utilizing Temperature Controlled Radio Frequency Surgery | $ 244,479.24 | |
| EndoSphere Inc. | SatiSphere Duodenal Insert | $ 221,690.50 | $ 22,788.75 |
| EnGen Bio, Inc. | Recombinant Human Albumin from an Optimized Expression Sstem | $ 244,479.24 | |
| Entelos Inc | Hematopiesis Compound Evaluation | $ 88,712.50 | |
| Entelos, Inc | Rheumatoid Arthritis Inflammatory Evaluation Project | $ 65,750.00 | $ 27,387.50 |
| Entelos, Inc | Rheumatoid Arthritis Inflammatory Targets Evaluatuion | $ 58,118.00 | |
| EntroGen Inc | development of a diagnostic test to aid in therapeutic decisions for colorectal cancer patients | $ 244,479.24 | |
| ENVY MEDICAL INC | Novel oligopeptides for the treatment and prevention of melanoma | $ 68,250.00 | $ 139,190.00 |
| Eos Neuroscience Inc. | Development of EOS-013, a Therapy to Restore Vision to Blind RP and AMD Patients | $ 53,377.13 | $ 191,102.12 |
| EPEIUS BIOTECHNOLOGIES CORPORATION | REXIN-G, TARGETED MOLECULAR GENE THERAPY FOR CANCER | $ 244,479.25 | |
| Epic Sciences, Inc. | CTC-HRP, predicting the response to anti-hormone receptor drugs in cancer patients | $ 226,377.50 | $ 18,101.75 |
| Epicardial Technologies Inc. | Epicardial Treatment and Diagnosis of Cardiac Arrhythmias | $ 244,479.24 | |
| Epicenter Software | Biologist Oriented Workbench for Genomic Integration. | $ 108,042.00 | $ 108,500.00 |
| Epigen Biosciences Inc. | Discovery and development of novel agents for the treatment of pruritis | $ 716.40 | |
| Epigen Biosciences, Inc. | Discovery and development of novel agents for the treatment of renal fibrosis | $ 3,023.16 | |
| Epinex Diagnostics, Inc | G1A Rapid Diabetes Monitoring Index Test | $ 244,479.24 | |
| Epiphany Biosciences, Inc. | Phase 2 Clinical Development of Valomaciclovir | $ 244,479.25 | |
| EPITOGENESIS INC | VACCINE FORMULATION | $ 244,479.25 | |
| Epitomics, Inc. | Development of Therapeutic Monoclonal Antibodies Against Her3 | $ 135,139.00 | $ 109,340.25 |
| Escape Therapeutics, Inc. | Development of an immune tolerant hESC source for allogeneic cell therapy applications | $ 242,668.26 | $ 1,810.98 |
| Essentialis, Inc. | Diazoxide Choline Controlled Release Tablets in the treatment of hypertriglyceridemia | $ 244,479.24 | |
| Eureka Therapeutics, Inc. | MAGE 101: A Next-Generation anti-Her2 Antibody for Metastatic Breast Cancer Treatment | $ 244,479.25 | |
| EVOKE PHARMA, INC | EVK-001 | $ 244,479.25 | |
| Excaliard Pharmaceuticals, Inc. | Anti-Fibrosis Skin Scarring | $ 244,479.24 | |
| Existence Genetics, LLC | Fully integrated and dynamic genetic testing, analysis, and reporting system | $ 87,449.20 | $ 157,030.05 |
| Expression Drug Designs | Biologic antagonism of S1P3 for the treatment of breast cancer | $ 45,866.49 | $ 54,844.39 |
| EyeCyte, Inc. | Drug-Mediated Cell Therapy For Diabetic Retinopathy | $ 244,479.24 | |
| Eye-Predict LLC | Assessing brain disorders based on natural gaze features | $ 42,139.00 | $ 202,340.25 |
| Fabrus LLC | Anti-Angiogenic DLL4 Antibody Therapy for Cancer | $ 244,479.25 | |
| Fallbrook Engineering Inc | Advanced Cord Blood Collection System | $ 108,145.50 | $ 95,902.00 |
| Fate Therapeutics, Inc | Novel bone Regenerative Therapy to Improve Healing and Reduce Healthcare Costs | $ 244,479.25 | |
| Fate Therapeutics, Inc | Novel Regenerative Therapeutic to Restore Pancreatic Function to Cure Diabetes | $ 244,479.25 | |
| Fate Therapeutics, Inc. | Patient-matched Cell Therapy to Cure Parkinson's Disease | $ 244,479.25 | |
| Fate Therapeutics, Inc. | Novel therapy Targeting Cancer Stem Cells to Treat Highly Aggressive Cancers | $ 244,479.25 | |
| Fate Therapeutics, Inc. | FT1050 to Improve Hematopoietic Stem Cell Transplants to Cure Leukemia/Lymphoma | $ 244,479.25 | |
| FEMTA PHARMACEUTICALS, INC | FM101:Anti human IL-6 Monoclonal Antibody | $ 244,479.24 | |
| Ferrokin BioSciences, Inc. | FBS0701:A novel iron chelator for the treatment of iron overload | $ 244,479.25 | |
| FFA Sciences LLC | Diagnosing Acute Coronary Syndromes | $ 44,864.50 | $ 158,370.50 |
| Fibrogen Inc | FG-65155 for treatment of ischemia reperfusion injury post-myocardial infarction | $ 244,479.25 | |
| FIBROGEN INC | Development of FG-3019 for treatment of locally advanced and metastatic pancreatic cancer | $ 244,479.25 | |
| Fibrogen Inc. | FG-6874 Development for the Treatment of Oncologic Anemias | $ 244,479.25 | |
| FIBROGEN INC. | FG-4592 Development for the treatment of Anemia of Chronic Kidney Disease | $ 244,479.25 | |
| Five Prime Therapeutics Inc | FP-1039 (FGFR1c:Fc), a Novel Anti-Cancer Agent Acting as an Antagonist of Multiple Fibroblast Growth Factor Ligands, for the Treatment of patients of with Advance CancerMalignancies. | $ 244,479.24 | |
| Five Prime Therapeutics, Inc | FP-1069 (CSF1Rc), a Novel Antagonist of CSC-1 and IL-34 for the Treatment of patients with Inflammatory Disease and Cancer. | $ 244,479.24 | |
| Flex Partners, Inc | Micro Fluidics Therapeutic Delivery Pump | $ 65,559.00 | $ 178,920.24 |
| Flow Pharma Inc. | Microencapsulation for Next Generation HIV Vaccine | $ 244,479.25 | |
| Flow Pharma, Inc. | Implantable, Microencapsulated Antibiotic | $ 244,479.25 | |
| Fluidigm Corporation | Non-invasive prenatal diagnostic development | $ 244,479.25 | |
| Fluigence, LLC | Development of a Handheld Bilirubin Bionsensor for Rapid Diagnosis of Neonatal Jaundice | $ 21,897.00 | $ 23,758.50 |
| Fluxion Biosciences, Inc. | The IsoFlux cancer diagnostic system | $ 244,479.25 | |
| ForSight VISION4, Inc | Rechargeable drug delivery device for treatment of ocular disease | $ 244,479.25 | |
| FP Technology | OCT-Based Non-Invasive Glucose Monitor | $ 137,617.50 | $ 106,861.75 |
| FQUBED Inc | fqubed's Development Project of NRI-1013 as a topical ibuprofen gel | $ 90,155.16 | $ 132,480.47 |
| FQUBED Inc | NRI-1018: Topical Etoricoxib for Treatment of Osteoarthitis | $ 139,127.99 | $ 105,351.26 |
| FQUBED, Inc | NRI-ANA: Topical Lidocaine for the Treatment of Acute Herpes Zoster | $ 63,888.97 | $ 133,330.84 |
| FQUBED, Inc | NuPro and OxoFoam for Improved Treatment of Chronic Wounds | $ 89,938.86 | $ 97,309.69 |
| FQUBED, Inc. | Effective Topical Treatment of Nail Fungal Infection | $ 110,959.88 | $ 109,943.72 |
| FQUBED, Inc. | Topical Diclofenac for Relief of Osteoarthritis | $ 244,479.25 | |
| FREEDOM MEDITECH INC | NON-INVASIVE OPHTHALMIC GLUCOSE MONITORING DEVICE | $ 53,896.16 | $ 74,430.37 |
| Freedom Meditech Inc | Non-Invasive Ophthalmic Diabetes Screening Device. | $ 31,180.54 | $ 74,031.12 |
| FZIOMED, INC. | OXIPLEX SPINE GEL | $ 244,479.24 | |
| Galaxy Biotech, LLC | Humanized monoclonal antibody to FGF receptor 2 for treatment of gastric and other cancers | $ 78,034.50 | $ 55,497.50 |
| Galaxy Biotech, LLC | Humanized monoclonal antibody to Sonic Hedgehog protein (SHH) for treatment of cancer | $ 106,162.50 | $ 95,657.50 |
| Galaxy Biotech, LLC | Humanized monoclonal antibody to FGF2 for treatment of hepatoma and other cancers | $ 61,817.50 | $ 40,705.50 |
| Galaxy Biotech, LLC | Humanized monoclonal antibody to Wnt co-receptor LRP6 for treatment of cancer | $ 13,123.50 | $ 92,915.00 |
| Gamma Medica -Ideas (USA) Inc | SPECT-MRI Hybirid Molecular Imaging | $ 84,754.00 | $ 158,494.00 |
| Gamma Medica-Ideas (USA) Inc | Molecular Breast Imaging | $ 244,479.25 | |
| Gamma Medica-Ideas (USA), Inc. | Translational Molecular Imaging | $ 244,479.25 | |
| GangaGen Inc. | Prevention and Treatment of Staphylococcus aureus (MRSA) infection | $ 244,479.24 | |
| Gemmus Pharma Inc | Novel treatment for influenza infections | $ 20,508.50 | $ 141,689.50 |
| Genalyte Inc | Silicon photonic sensor system for highly multiplexed diagnosis of multiple diseases | $ 244,479.24 | |
| GenapSys Inc | Development of inexpensive, ultra-high throughput micro-electronic medical DNA sequencer. | $ 244,479.25 | |
| GENE SECURITY NETWORK INC | ARRAY INFORMATICS TO UNDERSTAND PLOIDY CONCORDANCE | $ 196,010.00 | $ 48,469.25 |
| Gene Therapy Systems Inc | Creation & testing of a novel gene targeting vector for gene therapy | $ 84,060.99 | $ 84,643.75 |
| Gene Therapy Systems Inc | apid serodiagnostic test for active tuberculosis | $ 46,072.63 | $ 45,612.74 |
| Genefluidics Inc | Rapid phenotypic antibiotic susceptibility testing for evidence-based treatment for infection diseases. | $ 244,479.25 | |
| Genelux Corporation | GL-ONC1 | $ 244,479.24 | |
| Geron Corporation | GRNIC1: hESC-derived pancreatic islet cells for the treatment of diabetes | $ 244,479.24 | |
| Geron Corporation | GRNCM1: Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Disease | $ 244,479.24 | |
| Geron Corporation | GRNOPC1: hESC-derived oligodendrocyte progenitors for SCI & neurodegenerative disease | $ 244,479.24 | |
| Geron Corporation | GRNVAC1, autologous therapeutic cancer vaccine | $ 244,479.24 | |
| Geron Corporation | Imetelstat (GRN163L) | $ 244,479.24 | |
| GigaGen Inc. | Personalized Companion Diagnostics for Myelodysplastic Syndrome | $ 7,500.00 | $ 236,979.25 |
| Glaukos Corporation | The iStent® Trabecular Micro-Bypass Stent | $ 244,479.24 | |
| Glumetrics, Inc. | GluCath Intravascular Continuous Glucose Monitoring System | $ 244,479.24 | |
| GlySens Inc | Implantable Glucose Monitor for Therapeutic Furtherance | $ 244,479.25 | |
| GT LIFE SCIENCES, INC. | SYSTEMS BIOLOGY BASED BIOTHERAPEUTIC PRODUCTION | $ 244,479.25 | |
| Guided Delivery Systems, Inc | Subcutaneous Mitral Valve Repair | $ 244,479.25 | |
| HALCYON Molecular Inc | High-throughput single-molcule quantitative transcriptional profiling by EM | $ 244,479.25 | |
| Halcyon Molecular, Inc | DNA sequencing using electron microscopy | $ 244,479.25 | |
| Halozyme, Inc. & Subsidiary | Recombinant human hyaluronidase (rHuPH20) for subcutaneous drug delivery | $ 244,479.25 | |
| Halozyme, Inc. & Subsidiary | Recombinant Human Cathepsin L for the treatment of collegan deposition disorders | $ 244,479.25 | |
| Halozyme, Inc. and Subsidiary | PEGPH20, a novel treatment for solid tumors such as pancreatic cancer | $ 244,479.25 | |
| Halozyme, Inc. and Subsidiary | Insulin-PH20-Ultrafast insulin for superior glycemic control in the treatment of diabetes | $ 244,479.25 | |
| Hana Biosciences Inc | MARQIBO Cancer Therapeutic | $ 244,479.25 | |
| HANA BIOSCIENCES INC. | Alocrest Cancer Therapeutic | $ 148,327.67 | $ 67,373.84 |
| HANA BIOSCIENCES INC. | Menadione Topical Lotion | $ 244,479.25 | |
| Hansen Medical Inc | VASCULAR CATHETER CONTROL SYSTEM | $ 244,479.25 | |
| Harbor BioSciences Inc | Triolex | $ 244,479.25 | |
| Harbor BioSciences Inc | Apoptone | $ 244,479.25 | |
| Harbor Medical Inc DBA Sprixx | Sprizz hand hygiene system | $ 68,547.18 | |
| HEMO THERAPEUTICS | AQUAPHERESIS | $ 118,362.50 | |
| HOTSPUR TECHNOLOGIES INC | PTA-PLUS | $ 239,697.11 | $ 4,782.14 |
| HOTSPUR TECHNOLOGIES, INC | MACERATOR-ASPIRATOR | $ 244,479.25 | |
| Hotspur Technologies, Inc | EMBO-PLUS | $ 178,946.39 | $ 65,532.86 |
| Hotspur Technologies, Inc. | PTA DUO | $ 56,404.83 | $ 155,193.88 |
| HourGlass Technologies, Inc | Transoral Restrictive Intra Gastric Mesh Incisionless Gastric Banding system for weight loss | $ 244,479.25 | |
| Hunter Laboratories Inc | HunterHeart | $ 199,634.00 | $ 44,845.25 |
| Hunter Laboratories Inc | HPV OncoTect Cancer Detection Diagnostic | $ 244,479.25 | |
| Huya Bioscience International LLC | Development of HBI-8000: A Novel HDAC Inhibitor for Treatment of Cancer | $ 244,479.24 | |
| HydraDx Inc | Importance of HydraDx Dehydration Diagnostic For Diagnosis and Monitoring State of Hydration | $ 244,479.25 | |
| Hyperion Therapeutics, Inc. | HPN-100 (GPB) in Urea Cycle Disorders and Hepatic Encephalopathy | $ 244,479.25 | |
| ICB International Inc | Diagnosis and treatment of Alzheimer's disease (AD) | $ 244,479.24 | |
| Ichor Medical Systems Inc | Novel Delivery Platform for DNA Vaccine Delivery in Skin | $ 49,356.09 | $ 100,233.07 |
| Ichor Medical Systems, Inc | A xenogeneic DNA Vaccine for Melanoma | $ 53,672.80 | $ 91,831.78 |
| Ichor Medical Systems, Inc | IND-Enabling Biodistribution and Integration GLP Assays for DNA Drugs | $ 13,022.30 | $ 42,151.33 |
| Ichor Medical Systems, Inc | DNA Drugs Delivered with Novel Intramuscular Electroporation Technology | $ 117,452.35 | $ 117,648.59 |
| Ichor Medical Systems, Inc. | Therapeutic HBV DNA Vaccine Delivered withIchor's TDS Electroporation Technology | $ 106,663.02 | $ 137,816.23 |
| Icon Bioscience, Inc | Versiome Ophthalmic Drug Delivery System | $ 244,479.25 | |
| Icon Bioscience, Inc. | IBI-10090 for Intraocular Injection | $ 187,126.84 | $ 57,352.41 |
| Icon Bioscience, Inc. | IBI-20089 for Intravitreal Injection | $ 244,479.25 | |
| ID FISH Technologies, Inc. | Fluorescent in site hybridization assay kits (FISH kits) | $ 226,876.00 | $ 17,603.25 |
| Idolo Biotechnology LLC | Idolo | $ 35,000.00 | $ 57,933.50 |
| IGeneX, Inc | Bartonella FISH Diagnostic | $ 211,861.57 | $ 32,617.68 |
| Igenica, Inc | Novel Therapeutic Monoclonal Antibodies for Cancer | $ 244,479.25 | |
| Igenica, Inc. | Novel Monoclonal Antibody for Treating Acute Myelogenous Leukemia | $ 244,479.25 | |
| IGT LLC dba Eigen | Apollo: Robotic Needle Guidance System | $ 244,479.24 | |
| IGT, LLC dba Eigen | Artemis:3D Imaging Workstation | $ 244,479.24 | |
| Imaginab, Inc. | Contract Manufacturing of an in vivo Molecular Diagnostic for Imaging Agent of Prostate Cancer | $ 12,244.30 | $ 232,234.95 |
| Imaginab, Inc. | Contract Manufacturing of an in vivo Molecular Diagnostic for Imaging Autoimmune Disease | $ 111,251.62 | $ 133,227.63 |
| iMetrikus, Inc | System for Health Monitoring in Populations | $ 244,479.25 | |
| ImmPORT Therapeutics Inc. dba Antigen Discovery Inc | Novel non-invasive diagnostics for liver diseases | $ 94,750.00 | $ 149,729.25 |
| ImmPORT Therapeutics, Inc (dba) Antigen Discovery, Inc | Safe and efficacious vaccine against Chlymedia | $ 244,479.25 | |
| ImmPORT Therapeutics,Inc.(dba).Antigen Discovery. Inc. | Accurate and robust serodiagnostic test for Lyme Disease | $ 130,404.50 | $ 114,074.75 |
| ImmunGene Inc. | Development for the treatment of non-Hodgkins's lymphoma patients with genetic resistance. | $ 200,326.57 | $ 44,152.68 |
| ImmunoCellular Therapeutics Ltd | Development of a Cancer Vaccine for Glioblastoma (Brain Cancer) | $ 244,479.25 | |
| ImmunoScience, Inc. | Salivax | $ 244,479.25 | |
| IMTEC Biomedical Inc | IMTEC VasConnect and VasPort System for Vascular Access | $ 48,114.00 | $ 115,540.00 |
| Imthera Medical Inc | THN Sleep Therapy for Obstructive Sleep Apnea (OSA) | $ 244,479.24 | |
| IncellDx, Inc. | E6, E7 mRNA Cervical and Anal Cancer Diagnostic | $ 39,857.50 | $ 204,621.75 |
| Incline Therapeutics, Inc. | IT101 | $ 244,479.25 | |
| InCode BioPharmaceutics, Inc. | C3 Complement Depletor Project | $ 229,735.50 | $ 14,743.75 |
| Ingenuity Systems Inc | Drug Respositioning, Biomarker and Therapeutic Target Discovery Program | $ 244,479.25 | |
| Inhibrx, Inc | Development of a therapeutic antibody for the treatment of vascularized tumors | $ 244,479.25 | |
| Innovative Cell Technologies, Inc. | Developing Clinical Grade Cell Dissociation Reagent for Embryonic Stem Cell Manufacturing | $ 6,250.00 | $ 61,375.00 |
| Innovative Micro Technology Inc | Early cancer detection : A MEMS-based cell sorter for CTC enumeration and functional testing | $ 244,479.25 | |
| Insera Therapeutics, Inc. | Novel clot-retrieval and clot-filtering device for Stroke treatment including intra-arterial thrombolsys | $ 125,000.00 | $ 119,479.25 |
| InSite Medical Technologies, Inc. | Epiphany Epidural Access System | $ 136,117.00 | $ 108,362.25 |
| InSite Vision, Inc | ISV-303 Ocular Anti-Inflammatory Therapeutic | $ 244,479.25 | |
| InSite Vision, Inc. | ISV-502 Therapeutic for Blepharitis and Lid Margin Disease | $ 244,479.25 | |
| Inspiration Biopharmaceuticals, Inc | Recombinant Factor IX for the treatment of Hemophilia B | $ 244,479.25 | |
| Inspiration Biopharmaceuticals, Inc. | Recombinant Porcine Factor VIII (OBI-1) for the Treatment of Acquired Hemophilia | $ 244,479.25 | |
| Intarcia Therapeutics, Inc | Continuous, Subcutaneous Delivery of an Incretin Mimetic to Treat Type 2 Diabetes | $ 244,479.25 | |
| IntegenX Inc | Apollo 200 | $ 244,479.25 | |
| IntegenX Inc | Apollo 396 | $ 244,479.25 | |
| IntegenX Inc | Apollo 324 | $ 244,479.25 | |
| IntegenX, Inc | Apollo 100 | $ 244,479.25 | |
| Integrated Endoscopy, Inc | Single use HD Endoscope | $ 21,783.33 | $ 25,000.00 |
| Integrated Medical Systems Inc | Life Support for trauma and transport commercialization | $ 71,707.00 | |
| InteKrin Therapeutics Inc | INT131 A Safe Insulin Sensitizer for Treatment of Type 2 Diabetes | $ 244,479.25 | |
| Intellikine, Inc. | Development of INK1117 for treatment of hematologic malignancies | $ 132,457.00 | $ 112,022.25 |
| Intellikine, Inc. | Development of INK1117 for treatment of solid tumors | $ 244,479.25 | |
| Intellikine, Inc. | Development of INK1117 for treatment of solid tumors and hematologic malignancies | $ 244,479.25 | |
| Intellikine, Inc. | Development of INK1117 for treatment of rheumatoid arthritis | $ 244,479.25 | |
| Intermune Inc. | PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | $ 244,479.25 | |
| INTERMUNE, INC | Danoprevir Development Program | $ 244,479.25 | |
| Intermune, Inc. | Next Generation HCV Therapeutic Discovery Program | $ 244,479.25 | |
| International Stem Cell Corporation and Subsidiaries | hPSC | $ 244,479.25 | |
| Intersect ENT, Inc | SpiderRX | $ 244,479.25 | |
| Intersect ENT, Inc | CrownRX | $ 244,479.25 | |
| Interventional Spine Inc | Percudyn System ("PDS") | $ 244,479.25 | |
| Intradigm Corporation (Silence Therapeutics, plc) | Silence Therapeutics: Novel RNAi Therapeutics | $ 244,479.24 | |
| IntraOp Medical Corporation | Mobetron IOERT and Etanidazole Radiation Sensitizing Drug | $ 244,479.24 | |
| Intrinsic LifeSciences, LLC | Development of FDA-approved Hepcidin Diagnostic Devices for Clinical Medicine | $ 75,420.73 | $ 169,058.51 |
| Intuity Medical, Inc. | POGO™ | $ 244,479.25 | |
| Ion Torrent Systems, Inc. | Development of Next Generation Sequencing Platform for Molecular Diagnostic Applications | $ 244,479.25 | |
| iPierian Inc | New Drugs for Amyotrophic Lateral Sclerosis (ALS) Discovered using iPS Cells | $ 236,827.00 | $ 7,652.25 |
| iPierian, Inc. | New Drugs for Spinal Muscular Atrophy Discovered using Induced Pluripotent Stem Cells | $ 244,479.25 | |
| IR2DX Inc | Physician Office Metabolic Assessment | $ 37,500.00 | |
| IR2Dx, Inc | Laboratory Panel - Metabolic and Atherosclerlerosis Assessment | $ 111,500.00 | |
| iRhythm Technologies Inc. | The Zio [tm] Patch and ZEUS Project. | $ 244,479.24 | |
| IRIDEX Corporation | Premixed, Sterile Single Dose Gas (Eye Gas) for Treatment of Retinal Detachments | $ 58,853.87 | |
| Iris BioTechnologies, Inc. | Optimizing Personalized and Targeted Medical Treatment Using | $ 34,808.50 | $ 209,670.75 |
| iScience Interventional | iScience Microcatheter, for treatment of Macular Edema | $ 244,479.25 | |
| iScience Interventional | iSceince Canaloplasty Project | $ 244,479.25 | |
| Islet Sheet Medical LLC | Novel Islet Sheets Method for Treating Diabetes | $ 53,746.57 | $ 148,946.96 |
| Itero Biopharmaceuticals Inc | A newly formulated and differentiated recombinant follicle stimulating hormone, or rFSH. | $ 244,479.25 | |
| Itherx Pharmaceuticals | Development of Novel Entry Inhibitors for Hepatitis C | $ 244,479.25 | |
| IVANTIS INC. | Hydrus Aqueous Implant | $ 244,479.25 | |
| Jaden BioScience Inc AKA Jade BioScience inc | Ultrasensitive cell surface detection of B-cell chronic lymphocytic leukemia(B-CLL) | $ 26,089.00 | $ 57,115.50 |
| Jan Medical Inc. | Jan Medical DCX Project | $ 228,658.50 | $ 15,820.74 |
| Jazz Pharmaceuticals, Inc. | JZP-6 Sodium Oxybate for the Treatment of Fibromyalgia | $ 244,479.25 | |
| Jazz Pharmaceuticals, Inc. | PLE-1 Twice-Nightly Immediate Release Solid Oral Dosage Form of Sodium Oxybate | $ 203,019.50 | $ 41,459.75 |
| Jazz Pharmaceuticals, Inc. | JZP-8 Intranasal Clonazepam for the Treatment of Acute Repetitive Seizures | $ 218,133.00 | $ 26,346.25 |
| Jazz Pharmaceuticals, Inc. | PLE-2 Once-Nightly Controlled-Release Solid Oral Dosage Form of Sodium Oxybate | $ 147,883.00 | $ 96,596.25 |
| Jennerex Inc | Intravenous Treatment of Advanced Metastic Colorectal Cancer with JX-594 | $ 244,479.24 | |
| Jennerex Inc. | JX-2011: A Novel Product for Advanced Metastatic Prostate Cancer | $ 244,479.25 | |
| Jennerex, Inc | JX-594: A Novel Therapeutic for Direct Injection into Liver Tumor | $ 244,479.25 | |
| JN Biosciences, LLC | Development of an immunosuppressive therapeutic antibody | $ 109,300.00 | $ 135,179.24 |
| Juvaris Bio Therapeutics, Inc. | Use of JVRS-100 to protect against ionizing radiation | $ 244,479.25 | |
| Juvaris BioTherapeutics Inc | Use of JVRS-100 as an immunotherapeutic to treat Acute Myelogenous Leukemia | $ 244,479.25 | |
| Juvaris BioTherapeutics, Inc | Combination of JVRS-100 with Francisella tularensis membrane fraction | $ 244,479.25 | |
| Juvaris BioTherapeutics, Inc. | Use of JVRS-100 to protect against reperfusion injury | $ 244,479.25 | |
| KAI Pharmaceuticals, Inc | KAI-1678 for Neurpathic Pain | $ 244,479.25 | |
| KAI Pharmaceuticals, Inc. | KAI-9803 for Acute Myocardial Infarction | $ 244,479.25 | |
| KAI Pharmaceuticals, Inc. | KAI-4169 for Secondary Hyperparathyroidism (SHPT) | $ 244,479.25 | |
| KaloBios Pharmaceuticals, Inc. | Humaneered Monoclonal Antibody (KB003) for the Treatment of Rheumatoid Arthritis | $ 244,479.24 | |
| KaloBios Pharmaceuticals, Inc. | Therapeutic Antibody (KB004) FOR THE Treatment of Hematological Malignancies | $ 244,479.24 | |
| KaloBios Pharmaceuticals, Inc. | KB001-A for Treatment of Pseudomonas Aeruginosea in Cystic Fibrosis Patients | $ 244,479.24 | |
| KaloBios Pharmaceuticals, Inc. | KB001- A for Treatment of Mechanically Ventilated Patients | $ 244,479.24 | |
| Kalos Therapeutics, Inc | Kalos Therapeutics, Inc. Development of KT-220 | $ 66,633.00 | $ 177,846.25 |
| Kalypsys, Inc. | H4R Antagonist Project | $ 244,479.25 | |
| KenHealth LLC | Percutaneous Closure Device | $ 244,479.25 | |
| KeraMed Inc | New Artificial Cornea and Implantation Method for Treatment of Blindness | $ 152,044.12 | |
| Keren Parmaceutical, Inc. | Development of External Guide Sequence (EGS) therapeutics for inflammatory lung disease | $ 9,970.50 | $ 12,612.50 |
| KI Biotechnologies | Automated Hight Throughput cRBC Stem Cell Hematopoietic Processing System | $ 244,479.24 | |
| KM Biotech, Inc. | GM602 for treatment of Stroke and Parkinson's Disease indications | $ 244,479.25 | |
| Kona Medical | Noninvasive Device Based Treatment for Hypertension | $ 244,479.25 | |
| Konan Medical USA, Inc | Bionocular Analytic Dynamic Pupillometer | $ 115,000.00 | |
| Kythera Biopharmaceuticals Inc | Nanoencapsulation of Therapeutic Proteins | $ 196,473.00 | |
| Kythera Biopharmaceuticals Inc | ATX-101 | $ 244,479.24 | |
| Kythera Biopharmaceuticals, Inc | ATX-104 | $ 244,479.25 | |
| Kythera Biopharmaceuticals, Inc | ATX-202 | $ 244,479.24 | |
| LAAX, INC | STROKE- LAAX PROJECT | $ 244,479.25 | |
| LakePharma, Inc | Development of a Novel Recombinant Protein For The Treatment Of Diabetes And Cancer | $ 40,850.00 | $ 118,915.00 |
| Lasmed Limited Liability Company | Infrared diode-laser tools for pain diagnostics and management | $ 117,426.24 | $ 127,053.01 |
| LENR Solutions, Inc. | LENR LipoSector | $ 76,631.00 | $ 167,848.25 |
| Lerner Medical Devices, Inc | Targeted Phototherapeutic Treatment of Psoriasis at Home | $ 244,479.25 | |
| Leuchemix Inc | CLINICAL STUDIES OF THE NOVEL ANTI-CANCER AGENT LC-1 | $ 240,189.50 | $ 4,289.74 |
| Leukobyte, Inc. | CytoPaint Extreme Analysis Software for Flow Cytometry | $ 2,730.50 | $ 241,748.75 |
| Ligand Pharmaceuticals Inc | Selective Androgen Receptor Modulators (SARM), LGD-4033 | $ 244,479.25 | |
| LIGAND PHARMACEUTICALS INC | Thrombopoietin (TPO) LGD-4665 | $ 244,479.25 | |
| Ligand Pharmaceuticals Inc | DARA | $ 244,479.25 | |
| LIGAND PHARMACEUTICALS INC | Organon Collaboration | $ 244,479.25 | |
| Ligand Pharmaceuticals Inc | Erythropoietin (EPO) Research Program | $ 244,479.25 | |
| Limerick BioPharma Inc | LIM-075 ATP-binding cassette activator for safer immunosuppressant therapy in transplants | $ 244,479.25 | |
| Limerick BioPharma, Inc | Limerick's Lipid Chaperones for treating metabolic disorders | $ 244,479.25 | |
| Livermore Instruments, Inc. | BioAerosol Mass Spectrometry for Tuberculosis Diagnosis | $ 146,001.50 | |
| Loma Vista Medical, Inc | Mulit-Layer Medical Balloons | $ 244,479.24 | |
| Lonestar Heart Inc | Cardiogenic Stem Cell Modulators | $ 244,479.25 | |
| Lpath, Inc. | Development of ASONEP™ for the treatment of Cancer | $ 244,479.24 | |
| Lpath, Inc. | Development of iSONEP(TM) for the treatment of Age-related Macular Degeneration | $ 244,479.24 | |
| Lumen Therapeutics, LLC | Nona-L-Arginine for Prevention of Saphenous Vein Graft Disease | $ 53,472.49 | $ 82,801.38 |
| Luminous Medical Inc. | Luminous Blod Glucose Monitor (LBGM) | $ 244,479.25 | |
| Lutran Industries Inc. | DRH12 Acute Viral Nasopharyngitis | $ 244,479.25 | |
| Lutran Industries Inc. | DRH12 Chronic Bronchitis | $ 244,479.25 | |
| Lutran Industries Inc. | DRH12 Mother to Child Transmission of Gonorrhea | $ 244,479.25 | |
| Lutran Industries Inc. | DRH12 Mother to Child Transmission of Chlamydia | $ 244,479.25 | |
| Lutran Industries Inc. | DRH12 Mother to Child Transmission of Hepatitis | $ 244,479.25 | |
| Lutran Industries Inc. | DRH12 Mother to Child Transmission of HPV | $ 244,479.25 | |
| Lypro Biosciences Inc | Nano Disks | $ 220,262.84 | $ 24,216.40 |
| MabPrex, Inc. | Brain penetrating BMP-4 as a cancer stem cell differentiation therapy against glioblastoma | $ 22,494.00 | $ 221,985.24 |
| Mabvax Threapeutics Inc | Human Monoclonial Antibodies from Immunized patient Lymphocytes | $ 244,479.24 | |
| Mabvax Threapeutics, Inc | Phase II Clinical Trial to determine efficacy of a vaccine to prevent recurrent sarcoma carbohydrate antigens in stage IV patients rendered disease free with the objective of preventing recurrent sarcoma | $ 244,479.24 | |
| Madera Biosciences, Inc. | Small molecule angiogenesis inhibitors for cancer therapy | $ 1,481.13 | $ 8,500.00 |
| MagArray, Inc | Magnetic Nanoparticle Immunoassay System for Cancer Diagnostics | $ 189,439.67 | $ 55,039.57 |
| Magellan Spine Technologies, Inc | Magellan DART Technology | $ 244,479.24 | |
| Magnesensors, Inc | Optimized magnetic nanoparticle labels for ultra-sensitive magnetic detection of pathogens | $ 48,995.00 | |
| Magnesensors, Inc | Ultra-sensitive magnetic rare cell assays for leukemia | $ 201,707.50 | $ 42,771.75 |
| Magnesensors, Inc | Quantitive detection of nucleic acids without amplification for sepsis diagnostics | $ 38,479.00 | |
| Magnetecs Corporation | Catheter guidance control & imging appartatus(CGCI) | $ 244,479.25 | |
| MandalMed, Inc. | Galectin-3C for treatment of cancer and prevention of metastasis | $ 30,264.00 | $ 4,486.00 |
| MAP Pharmaceuticals Inc | LEVADEX ™ | $ 244,479.25 | |
| Mapp Biopharmaceutical Inc | Vaginal Microbicide Antibodies | $ 102,274.34 | $ 9,063.39 |
| Mapp Biopharmaceutical, Inc | Biodefense Monoclonal Antibodies | $ 244,479.25 | |
| Mapp Biopharmaceutical, Inc | Clostridium Difficile Monoclonal Antibodies | $ 244,479.25 | |
| Mapp Biopharmaceutical, Inc | Alzheimer's Monoclonal Antibodies | $ 151,031.76 | $ 93,447.49 |
| Mapp Biopharmaceutical, Inc. | Respiratory Synctial Virus Antibodies | $ 14,598.24 | |
| Mariposa Biotechnology Inc | Automated osmolaltiy control for cryogenic freezing or thawing | $ 244,479.25 | |
| Masimo Laboratories, Inc | Improved Glucose Strip Reader | $ 244,479.25 | |
| Masimo Laboratories, Inc. | Glucose 1 Non-Invasive Glucose Diagnostic Device | $ 244,479.25 | |
| Matrix Sensors, Inc. | Matrix Sensors, Inc. | $ 244,479.25 | |
| Maven Technologies LLC | LFIRE | $ 197,015.00 | $ 47,464.25 |
| Maya Medical Inc | Maya System | $ 244,479.25 | |
| Medbiocom | Selective tumor vascular thrombogen | $ 244,479.24 | |
| Medbiocom | Anti cancer prodrug activated by proteases of the coagulation cascade | $ 244,479.25 | |
| Medbiocom | Cancer immune therapy targeting tumor associated macrophage | $ 244,479.25 | |
| Medical Tactile Inc | SureTouch breast cancer detection and diagnostics | $ 95,483.73 | $ 148,995.51 |
| MEDIVATION NEUROLOGY, INC | Dimebon for the treatment of Huntington Disease | $ 244,479.25 | |
| MEDIVATION NEUROLOGY, INC | Dimebon for the treatment of Alzheimer's Disease | $ 244,479.25 | |
| Medivation Prostate Therapeutics Inc | MDV3100 for the treatment of advanced prostate cancer | $ 244,479.25 | |
| MedSolve Technologies, Inc | Low Cost Micro Infusion Pump for the Treatment of Diabetes (Type 1 and Type 2) | $ 35,412.50 | |
| Mercator MedSystems, Inc. | Catheter-directed renal sympathectomy to reduce hypertension | $ 45,642.09 | $ 198,837.16 |
| MERITAGE PHARMA, INC | ORAL VISCOUS BUDESONIDE | $ 244,479.24 | |
| Metabasis Therapeutics Inc | Thyroid Receptor-beta Agonist | $ 244,479.25 | |
| METABASIS THERAPEUTICS INC | Glucagon Receptor Agonist Program | $ 244,479.25 | |
| Metabolex Inc | Development of MBX-3254 a GPR119 receptor agonist for the treatment of Type 2 Diabetes | $ 185,654.00 | |
| Metabolex Inc | Development of MBX-2982 a GPR119 agonist for the treatment of Type 2 Diabetes | $ 244,479.24 | |
| Metabolex Inc | Small molecule agonists of the bile acid receptor GPR131 for the treatment of type 2 diabetes | $ 125,300.00 | $ 119,179.24 |
| Metabolex Inc | Development of MBX-102 for the treatment of gout. | $ 244,479.24 | |
| Metabolex Inc | Agonists of the anti-lipolytic receptor GPR81 for the treatment of Coronary Artery Disease | $ 43,000.00 | |
| Metabolex Inc | Agonists of the fatty acid receptor GPR 120 for the treatment of type 2 diabetes | $ 244,479.24 | |
| Metabolex, Inc. | Development of TRPM5 Activators for the treatment of Type 2 Diabetes | $ 229,396.00 | |
| Metabolex, Inc. | MBX-8025 is a potential first-in-class therapy to treat mixed dyslipidemia | $ 244,479.24 | |
| Metronom Health, Inc. | Continuous Glucose Monitoring System with Hypoglycemic Detection | $ 244,479.25 | |
| MiCardia Corporation | MiCardia Encor Dynamic Heart Valve Repair Technology | $ 244,479.24 | |
| MicroCube LLC | A Novel device("Wrist") for precise delivery of therapeutics/devices | $ 147,000.00 | $ 97,479.25 |
| MicroCube LLC | Novel Office-based Menorrhagia Treatment | $ 244,479.25 | |
| Micropoint Bioscience, Inc | Developing POC In-Vitro Diagnostic Rapid Tests of Chronic and Acute Diseases | $ 244,479.25 | |
| MINDFRAME, INC | Mindframe Interventional Recanalization is Ischemic Stroke (IRIIS) System | $ 244,479.25 | |
| Minerva Surgical, Inc | Aurora System | $ 244,479.25 | |
| MingSight Pharmaceuticals | MS-553, A Novel Oral Therapy For the Treatment of Diabetic Eye Diseases and Uveitis | $ 61,901.00 | |
| Minnow Medical Inc | Peripheral Vascular System (PVS) | $ 244,479.24 | |
| Mitos Pharmaceuticals, Inc | Use of Tempol to improve radiation treatments in head, neck, breast, and brain cancer. | $ 244,479.24 | |
| MLC Dx Inc | DNA sequencing based recurrence test for Non-Hodgkin lymphoma | $ 92,909.48 | $ 151,569.77 |
| Modulated Imaging Inc | Advanced Medical Camera for Tissue Health Assessment | $ 69,673.50 | $ 154,201.00 |
| Molecular GPS Technologies and Subsidiaries | Molecular GPS Technologies' Influenza Vaccine 1230 Project | $ 231,861.17 | $ 12,618.08 |
| Molecular GPS Technologies and Subsidiaries | Molecular GPS Technologies' Aspergillus Program | $ 170,310.90 | $ 42,500.00 |
| Molecular GPS Technologies and Subsidiaries | Minisurf™ and Minisurf-R™ | $ 136,453.51 | $ 108,025.74 |
| Molecular GPS Technologies and Subsidiaries | Development Project of a New HSV2 Vaccine for Herpes genitalis (GH) | $ 146,616.47 | $ 97,862.78 |
| Molecular Imaging and Therapeutics, Incorporated | Development of single chain antibody conjugates against a unique prostate cancer antigen | $ 244,479.25 | |
| Molecular Response, LLC | Tumor Anatomy Characterization - Developing a Validated Test for EGFRi Therapies | $ 244,479.25 | |
| Molecular Response,LLC | Gene Expression Tests for Pedicting Lung Cancer Patient to EGFRi and HSP90i Therapy | $ 244,479.25 | |
| Mountain View Pharmaceuticals, Inc. | PharmaPEG Technology for PEG-protein Drug Conjugates with Decreased Immunoreactivity | $ 122,810.00 | $ 121,669.25 |
| Moximed, Inc | Kinespring Knee implant system | $ 244,479.25 | |
| Mpex Phamaceuticals, Inc. | AEROQUIN TM (MP-376: Levofloxacin Inhalation Solution) | $ 244,479.25 | |
| Multimeric Biotherapeutics, Inc. | Precision immunization vaccine for nicotine and other drugs of abuse | $ 3,518.68 | $ 77,251.04 |
| MyeloRx LLC | Development of a triptolide derivative for acute myeloid leukemia and other cancers | $ 32,748.00 | $ 211,731.24 |
| Mynosys Cellular Devices Inc | Surgical Device For The Treatment Of Childhood Blindness Due to Lens Cataract | $ 80,050.00 | $ 164,429.24 |
| NanoComposix, Inc | Hollow Porous Silica Nanoparticles (HOPS Nanoparticles) | $ 24,617.32 | $ 82,257.18 |
| NanoComposix, Inc. | Gold Nanoparticle Matrices for MALDI-MS Diagnostic Applications | $ 120,956.26 | $ 101,819.19 |
| NanoIVD, Inc | Nanotechnology-based Cancer IVD Platform and Point-of-care Test | $ 244,479.24 | |
| NANOMIX, INC. | Cardiac early detection biosensor | $ 244,479.24 | |
| NanoPacific Holdings, Inc | Nanodevice Cancer Drug Delivery | $ 244,479.25 | |
| Nanostim Inc | Nanostim's Leadless Cardiac Pacemaker | $ 244,479.25 | |
| NANOVASC INC | NANOVASC DRUG-ELUTING VASCULAR GRAFT | $ 244,479.24 | |
| Napo Pharmaceuticals, Inc | Development of crofelemer for treatment of secretory diarrhea | $ 244,479.25 | |
| Nativis Inc | Digitax Therapeutic Treatment for Brain Cancer | $ 244,479.25 | |
| Nativis, Inc | a-PCSK9s Therapeutic Treatment for Hypercholesterolemia | $ 244,479.25 | |
| Navigenics, Inc. | Navigenics pharmacogenomics panel to predict medication response and risk of side effects | $ 244,479.25 | |
| NAVISCAN,INC | POSITRON EMISSION MAMMOGRAPHY SCANNER FOR BREAST CANCER DIAGNOSIS | $ 244,479.25 | |
| Neodyne Biosciences, Inc | Neodyne Device for Improved Healing and Scar Reduction | $ 244,479.25 | |
| NEOLAC, INC. | PURIFIED SECRETORY IMMUNOGLOBIN TO PREVENT & TREAT NECROTIZING ENTERCOLITIS | $ 11,350.09 | $ 233,129.16 |
| Neonc Technologies, Inc | Development of Intranasal Delivery to the Brain | $ 49,029.00 | $ 195,450.25 |
| Neostasis Inc | T15 monoclonal antibody for the treatment of audioimmune disease. | $ 244,479.25 | |
| NeoSync Inc | Neuro-EEG Synchronization Therapy | $ 244,479.25 | |
| NeoVista, Inc. | CABERNET | $ 244,479.24 | |
| Nereus Pharmaceuticals, Inc | Marizomib (NPI-0052 | $ 244,479.25 | |
| NEREUS PHARMACEUTICALS, INC. | PLINABULIN | $ 244,479.25 | |
| Neugenesis Corporation | Development of a Recombinant Influenza Virus-Like Particle Pandemic(H5N1)Vaccine | $ 244,479.25 | |
| NEUGENESIS CORPORATION | Development of a cost effective polyclonal therapeutic against MRSA | $ 55,398.00 | $ 189,081.25 |
| Neugenesis Corporation | Develop Recombinant Virus-Like Particle Trivalent Seasonal Influenza Vaccine | $ 244,479.25 | |
| Neumedicines Inc | NM-Gene Therapy | $ 85,975.29 | $ 43,947.23 |
| Neumedicines, Inc | HHS1: Characterization and Manufacturing Development of a Novel Anti-Tumor Therapeutic | $ 23,414.67 | $ 114,553.90 |
| Neumedicines, Inc. | HemaMax Advancement for Multiple Unmet Medical Needs in hematology/Oncology | $ 244,479.24 | |
| Neuralieve, Inc. | Single pulse transcranial magnetic stimulation device for treatment/management of migraine. | $ 244,479.25 | |
| Neuraltus Pharmaceutical, Inc | Neuraltus NP003 - Developing a treatment for Lysosomal Storage Disorders | $ 176,543.50 | $ 67,935.74 |
| Neuraltus Pharmaceuticals, Inc. | Neuraltus NP001 - Developing a treatment for ALS and other neurodegenerative diseases | $ 244,479.24 | |
| Neuraltus Pharmaceuticals, Inc. | Neuratus NP002 - A treatment for dyskinesias caused by l-dopa treatment of Parkinson's | $ 244,479.24 | |
| Neurocine Biosciences, Inc | Development of GnRH antagonists (Elagolix) for endometriosis related pain | $ 244,479.24 | |
| Neurocrine Biosciences Inc | Development of G protein-coupled receptor agonists or antagonists | $ 244,479.24 | |
| Neurocrine Biosciences, Inc. | Development of Selective GPR119 Receptor Agonists for the Treatment of Type 2 Diabetes | $ 244,479.24 | |
| Neurocrine Biosciences, Inc. | Development of VMAT 2 inhibitors for hyperkinetic movement disorders | $ 244,479.24 | |
| NEUROGEN CORPORATION | Aplindore | $ 244,479.25 | |
| Neurogenetic Pharmaceuticals, Inc. | Novel therapeutics for the prevention of Alzheimer's disease | $ 169,963.00 | $ 74,516.24 |
| NeurogesX Inc | Quetenza (capsaicin)8% patch | $ 244,479.25 | |
| NEUROGESX, INC | NGX-1998-LIQUID HIGH CONCENTRATION TOPICAL CAPSAICIN | $ 156,101.50 | $ 88,377.75 |
| NeurogesX, Inc. | Acetaminophen Prodrugs | $ 6,408.00 | $ 137,913.00 |
| NeuroPace,Inc. | Responsive Neurostimulator Systems for Treating Neurological Diseases | $ 244,479.25 | |
| Nevro Corporation | Senza SCS | $ 244,479.25 | |
| NewLife Sciences LLC, dba Scientific Imaginetics | Final Phase Full-Scale US Launch of TMR Technology | $ 244,479.25 | |
| NEXMED | PREVONCO FOR THE TREATMENT OF LIVER CANCER | $ 244,479.25 | |
| NEXMED | Femprox for female sexual arousal disorder | $ 244,479.25 | |
| NEXMED Inc | VITAROS FOR REYNAUD'S PHENOMENON | $ 244,479.25 | |
| NextWave Pharmaceuticals Inc | Methylphenidate HCI Extended-Release Powder for Oral Suspension | $ 244,479.25 | |
| NextWave Pharmaceuticals Inc | Mexocopm XR Tablet - clonidine extended release tablet | $ 244,479.25 | |
| NextWave Pharmaceuticals Inc | Methylphenidate Extended Release Chewable Tablet | $ 25,766.50 | $ 218,712.75 |
| NextWave Pharmaceuticals Inc | Nexiclon XR Liquid - clonidine extended release liquid suspension | $ 244,479.25 | |
| NextWave Pharmaceuticals, Inc. | Dexmethylphenidate Extended Release Formulation | $ 57,486.00 | $ 186,993.25 |
| Nexus Dx Inc | High Sensitivity cardiac panel | $ 244,479.25 | |
| Nexus Dx Inc | Flu-ID | $ 244,479.25 | |
| NGM Biopharmaceuticals | NPT1162 for Type 2 Diabetes Mellitus | $ 244,479.25 | |
| NGM Biopharmaceuticals, Inc. | Disease Modifying Therapeutics for Type 2 Diabetes Mellitus | $ 244,479.25 | |
| NGM Biopharmaceuticals, Inc. | Therapeutics to Enhance Compromised Muscle Function | $ 244,479.25 | |
| Nile Therapeutics, Inc | CD-NP-Acute Heart Failure | $ 244,479.24 | |
| NOCIMED LLC | NOCISCAN-MR Spectroscopy for Molecular Diagnosis of Discogenic Low Back Pain | $ 233,732.16 | $ 10,747.09 |
| Nodality Inc | Development of Molecular Diagnostics for Prediction of Treatment Response in AML | $ 244,479.24 | |
| Nodality Inc | Molecular Diagnostics for Patient-Specific Characterization of Immune Dysfunction | $ 74,491.00 | $ 169,988.24 |
| Nodality Inc | Molecular Diagnostics for Drug Pathway Profiling in Hematologic Malignancies | $ 244,479.24 | |
| Nodality Inc | Development of Molecule Diagnostics for Prediction of Treatment Response in MDS | $ 244,479.24 | |
| Nodality Inc | Molecular Diagnostics for Prediction of Disease Progression and Treatment Response in CLL | $ 244,479.24 | |
| NovaBay Pharmaceuticals, Inc. | Treatment of Impetigo | $ 244,479.24 | |
| NovaRx Corporation | Pivotal phase III clinical trial of Lucanix for non-small cell lung cancer | $ 244,479.24 | |
| Novelix Pharmaceuticals, Inc. | NVX-207 | $ 16,741.00 | $ 227,738.25 |
| Novici Biotech, LLC | Empirical Codon Optimization Technology for Biopharmaceutical & DNA Vaccine Improvement | $ 36,662.00 | |
| NovoMedix , LLC | Treatment of Triple Negative Breast Cancer | $ 5,060.50 | $ 95,729.00 |
| NovoMedix, LLC | Treatment of Type II Diabetes | $ 155,828.00 | $ 26,264.50 |
| NuCardia Inc | HeartFlow | $ 244,479.24 | |
| NuMask, Inc. | NuMask IntraOral Mask and Oropharyngeal Airway Research and Development | $ 71,187.50 | |
| NuMask, Inc. | NuMask IntraOral Mask and Oropharyngeal Airway, Clinical Research | $ 142,829.50 | |
| Numedii | using computational drug repositioning to develop novel lung cancer therapeutics | $ 4,150.00 | $ 240,329.25 |
| Numerate Inc | Novel drug products for treating latent and drug-resistant tuberculosis | $ 170,689.46 | $ 73,789.78 |
| Numerate, Inc | A novel drug for treating celiac sprue | $ 159,084.28 | $ 85,394.97 |
| Numerate, Inc. | A novel drug for treating hepatitis C virus infections | $ 189,658.15 | $ 54,821.09 |
| Nuon Therapeutics Inc | NU3450 (tranilast) for the treatment of rheumatoid arthritis | $ 244,479.25 | |
| Nuon Therapeutics Inc. | NU1618 for the treatment of chronic gout | $ 244,479.25 | |
| Nuveta, Inc | IVF Technology | $ 96,446.81 | $ 21,883.50 |
| Ocera Therapeutics Inc | OCR-002 for Hyperammonemia & Resultant Hepatic Encephalopathy in Chronic Liver Disease | $ 244,479.25 | |
| Ocera Therapeutics Inc | OCR-002 for Hyperammonemia & Resulant Hepatic Encephalopathy in Acute Liver Failure | $ 244,479.25 | |
| Ocera Therapeutics Inc | AST-120 for the Treatment of Non-Constipating Irritable Bowel Syndrome (nc-IBS) | $ 244,479.25 | |
| Odyssey Thera, Inc | miRNA Oncology Target Validation and Therapeutic Development | $ 244,479.25 | |
| Odyssey Thera, Inc. | Development of Multi-Targeted Oncology Therapeurics | $ 244,479.25 | |
| Olema Pharmaceuticals, Inc. | Oral Complete Anti-estrogens for the Treatment of Metastatic Breast cancer | $ 144,092.60 | $ 100,386.65 |
| Oligasis, LLC | A breakthrough technology for pharmaceuticals: Validating and commercializing an enabling platform and manufacturing technology in collaboration with multiple pharmaceutical partners. | $ 244,479.24 | |
| Omniox, Inc. | Overcoming Tumor Hypoxia with OMX-0004 to Revolutionize Chemo/Radiation Outcomes | $ 230,794.86 | $ 13,684.38 |
| Omnueron Inc | Therapeutic Technology for Real Time Functional MRI | $ 244,479.25 | |
| OMP, Inc | Treatment for Melasma, NuDerm | $ 244,479.25 | |
| On Demand Therapeutics, Inc | Laser activated, opthhalmic drug delivery implant for treating retinal diseases | $ 244,479.25 | |
| Oncolytics Biotech (U.S..) Inc. | Reolysin | $ 244,479.24 | |
| OncoMed Pharmaceuticals Inc. | OMP-21M18: Targeting DLL4 in Cancer Stem Cells for the treatment of cancer. | $ 244,479.24 | |
| OncoMed Pharmaceuticals, Inc | OMP-59R5: Targeting Notch Receptors in Cancer Stem Cells for the treatment of Cancer | $ 244,479.24 | |
| OncoMed Pharmaceuticals, Inc | Antibodies Targeting Notch Pathway Ligands for the Treatment of Cancer | $ 244,479.24 | |
| OncoMed Pharmaceuticals, Inc | Inhibiting the Wnt Pathway for the Treatment of Cancer | $ 244,479.24 | |
| OncoMed Pharmaceuticals, Inc. | OMP-18R5 Targeting the Wnt Pathway in Cancer Stem Cells for the Treatment of Cancer | $ 244,479.24 | |
| OncoTx Inc | Isoforms of gene transcription proteins: Development of novel tools for cancer diagnosis | $ 107,777.00 | $ 136,702.25 |
| Onset Medical Corporation | Onset Controlled Deployment Technology | $ 244,479.25 | |
| Opal Therapeutics Inc | Opal HIV - An Immunotherapy for HIV | $ 11,469.50 | $ 64,335.00 |
| Open Monoclonal Technology Inc | Monoclonal Antibody Cocktail Therapy | $ 244,479.25 | |
| Ophidion, Inc. | Novel Cholinergic Therapeutics for Cognitive Enhancement | $ 111,568.50 | $ 97,650.00 |
| Optimedica Corporation | Image-guided femtosecond laser cataract surgery | $ 244,479.25 | |
| Optimer Pharmaceutical, nc. | Fidaxomicin, a novel therapy for Clostridium difficile infections (CDI) | $ 244,479.25 | |
| OptiScan Biomedical Corporation | Closed Loop Insulin delivery with an ICU Continuous Glucose Monitor | $ 244,479.24 | |
| Optovue Inc | iVue | $ 244,479.25 | |
| OPTOVUE, Inc | ACVUE | $ 85,382.00 | $ 159,097.25 |
| Opus Pharmaceuticals, Inc | L-FABP drugs as novel therapeutics for fatty liver disease, elevated lipids and obesity | $ 49,880.50 | $ 44,768.00 |
| Oramic, LLC | Electro-Fluidic Thrombolysis microcatherter for the clearing of vascular occlusions | $ 20,138.50 | $ 109,700.00 |
| O-Ray Pharmaceuticals | Sustained Release Inner Ear Delivery of Corticosteroid | $ 22,500.00 | $ 101,966.67 |
| Orexigen Therapeutics, Inc | Contrave | $ 244,479.24 | |
| Orexigen Therapeutics, Inc. | Empatic | $ 244,479.24 | |
| Organovo Inc | Biological 3D Bioprinted Blood Vessel | $ 152,808.68 | |
| Organovo Inc | NovoGen 3D Bioprinter Development | $ 184,735.50 | $ 59,743.75 |
| Orphagen Pharmaceuticals | Novel Small Molecule Drug Class for the Treatment of Retinal Degeneration | $ 88,752.50 | $ 57,265.00 |
| Orphagen Pharmaceuticals | Novel Small Molecule Drug Class for the Treatment of Autoimmune Disease | $ 176,533.50 | $ 67,945.75 |
| Orphagen Pharmaceuticals | A novel drug class for treating adrenocortical cancer, prostate cancer and endometriosis. | $ 29,494.00 | $ 202,980.50 |
| ORTHALIGN, INC. | KneeAlign | $ 244,479.25 | |
| Osel, Inc. | LACTIN-V-Preventing Recurrence of Female Urinary Tract Infections | $ 162,466.00 | $ 33,378.00 |
| Osel, Inc. | MucoCept-Development of a Novel Anti-HIV Microbicide | $ 244,479.24 | |
| Osseon Therapeutics, Inc. | Osseoflex Balloon Tamp | $ 142,500.00 | |
| Otonomy, Inc | OTO-203: Ciprofloxation + Dexamethasone Gel for Use During Tympanostomy Tube Surgery | $ 244,479.24 | |
| Otonomy, Inc. | OTO-104: Sustained Release Dexamethasone Gel for Treatment of Meniere's Disease | $ 244,479.24 | |
| OvaGene Oncology | Creation of a Cell Line System for Companion Diagnostic Development | $ 125,000.00 | |
| OvaGene Oncology | Validation of STMN1 as a Predictor of Endometrial Cancer Recurrence | $ 147,500.00 | |
| OvaGene Oncology | Molecular Definition of Atypical Endometrial Hyperplasia | $ 244,479.24 | |
| OXiGENE, Inc | Development of CA4P as a Topical Treatment for Abnormal Vascular Ophthalmic Diseases | $ 244,479.24 | |
| OXiGENE, Inc | Development of CA4P for the Treatment of Solid Tumor Cancers | $ 244,479.24 | |
| OXIGENE, Inc. | Development of CA1P (OXi4503) for the Treatment of Solid Tumor and Hemotologic Cancers | $ 244,479.24 | |
| Pacira Pharmaceuticals Inc | DepoNSAID - sustained release drug for improved treatment of pain and inflammation | $ 35,796.71 | $ 46,464.93 |
| Pacira Pharmaceuticals, Inc | EXPAREL™ -sustained release drug for postoperative pain relief and reduced opiod usage | $ 244,479.25 | |
| Pacira Pharmaceuticals, Inc. | DepoMTX - sustained release drug for rheumatoid arthritis | $ 124,187.58 | $ 61,706.39 |
| Pain Therapeutics | PTI-721 | $ 111,513.00 | $ 132,966.24 |
| Pain Therapeutics Inc | PTI-421 | $ 116,870.00 | $ 127,609.24 |
| Pain Therapeutics, Inc | PTI-320 | $ 244,479.24 | |
| Pain Therapeutics, Inc | Remoxy | $ 244,479.24 | |
| Pain Therapeutics, Inc | Alzheimer's Treatment | $ 11,745.00 | $ 31,918.50 |
| Pain Therapeutics, Inc. | PTI-301 | $ 244,479.24 | |
| Pain Therapeutics, Inc. | PTI-221 | $ 117,643.00 | $ 126,836.24 |
| Pain Therapeutics, Inc. | PTI-DX304 | $ 38,630.00 | $ 21,335.00 |
| Pain Therapeutics, Inc. | PTI-609 | $ 244,479.24 | |
| Pain Therapeutics, Inc. | PTI-303 | $ 244,479.24 | |
| Panorama Research, Inc | Inotropic Antibodies | $ 40,293.65 | $ 59,329.81 |
| Panorama Research, Inc | Novel Multiplex Assay for Biomarkers of Alzheimer's Disease | $ 5,988.08 | $ 72,399.00 |
| Panorama Research, Inc | Novel Therapy for Pemphigus Vulgaris by Treatment with a Cholinergic Agonist | $ 7,193.96 | $ 77,883.00 |
| Panorama Research, Inc | Novel TACE Inhibitors for Breast Cancer Therapy | $ 61,536.98 | $ 24,611.43 |
| Panorama Research, Inc | Novel Therapy for Diabetic Complications Using RAGE-Fc | $ 168,624.62 | $ 69,362.00 |
| Panorama Research, Inc | Kinetic Assembly of Bispecific Antibodies | $ 76,103.69 | |
| Panorama Research, Inc | Myocardial Repair by Targeted Stem Cells | $ 244,479.25 | |
| Panorama Research, Inc | Multiplex Biomarkers for Prostate Cancer | $ 49,054.35 | $ 38,586.50 |
| Panorama Research, Inc. | Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis | $ 34,111.23 | $ 147,003.00 |
| Paracor Medical, Inc. | HeartNet System | $ 244,479.24 | |
| Parallel Synthesis Technologies Inc | Multiplex Serodiagnostic Test for Chagas Disease | $ 244,479.25 | |
| Pathologica, LLC | Pathologica | $ 244,479.25 | |
| Pathwork Diagnostics, Inc | Tissue of Origin Test | $ 244,479.24 | |
| Paul H Chen | Corneal Epithelial Transplant Device-Jet Contact Lens | $ 244,479.25 | |
| Pavilion Medical Innovations LLC | Pavilion Reversible Vena Cava Filter | $ 64,964.50 | $ 179,514.74 |
| PaxVax Inc | PaxVax - Cholera Vaccine | $ 93,760.50 | $ 150,718.75 |
| PaxVax, Inc | PaxVax - influenza vaccines | $ 244,479.25 | |
| PaxVax, Inc | PaxVax - HIV Vaccine | $ 83,323.00 | $ 161,156.25 |
| PaxVax, Inc. | PaxVax - anthrax vaccine | $ 244,479.25 | |
| PEAK Surgical, Inc. | PEAK Plasmablade Improving Patient Treatment Outcomes | $ 244,479.25 | |
| Pearl Therapeutics, Inc. | PT003 - formoterol-glycopyrrolate combination HFA-MDI for COPD | $ 244,479.25 | |
| Pearl Therapeutics, Inc. | PT001- glycopyrrolate HFA-MDI for treatment of COPD | $ 244,479.25 | |
| Pearl Therapeutics, Inc. | PT010 - formoterol/glycopyrrolate/mometasone combination HFA-MDI for COPD | $ 96,654.00 | $ 147,825.25 |
| PENUMBRA INC | THE PENUMBRA EMBOLIZATION SYSTEM | $ 244,479.25 | |
| PENUMBRA, INC. | THE PENUMBRA SYSTEM | $ 244,479.25 | |
| Peregrine Phamaceuticals Inc | Bavituximab for the treatment of Refractory of Non-small Cell Lung Cancer | $ 244,479.25 | |
| Peregrine Pharmaceuticals Inc | Bavituximab for the treatment of Non-Small Lung Cancer (Front-line Therapy) | $ 244,479.25 | |
| Peregrine Pharmaceuticals Inc | Bavituximab for the treatment of patients Co-infected with HCV-HIV | $ 238,783.50 | $ 5,695.75 |
| Peregrine Pharmaceuticals, Inc | Cotara for the treatment of Glioblastoma Multiforme (GBM) | $ 244,479.25 | |
| Perseid Therapeutics LLC | BA | $ 96,183.50 | $ 148,295.74 |
| Perseid Therapeutics LLC | PTLA | $ 37,850.50 | $ 206,628.74 |
| Perseid Therapeutics LLC | Maxy-4 | $ 244,479.24 | |
| Phage Pharmeceuticals | Therapuetic treatment of chronic tympanic membrane perforation by fibroblast growth factor. | $ 244,479.25 | |
| PharmacoFore, Inc. | Tamper-and-Abuse-Resistant Hydromorphone Prodrug | $ 244,479.25 | |
| PharmacoFore, Inc. | PF0713: Safer IV Sedative-Hypnotic Agent | $ 244,479.25 | |
| PharmacoFore, Inc. | PF03 MPAD: Multi-Pill Abuse-Deterrent (MPAD) Hydromorphone Prodrug | $ 213,354.73 | $ 31,124.52 |
| Pharmaco-Kinesis Corporation | Metronomic Biofeedback Pump (MBP) | $ 244,479.25 | |
| Pharmacyclics Inc | Factor Vlla Inhibitor PCI-27483 | $ 244,479.25 | |
| Pharmacyclics Inc | HDAC Inhibitor PCI-24781 | $ 244,479.25 | |
| Pharmacyclics, Inc. | Btk Inhibitor PCI-32765 | $ 244,479.25 | |
| Pherin Pharmaceuticals, Inc. | PH80 | $ 102,708.25 | |
| Pherin Pharmaceuticals, Inc. | PH94B | $ 131,068.25 | |
| PHILOMETRON INC | VENOUS STASIS ULCER THERAPY MANAGEMENT SYSTEM | $ 68,413.00 | $ 28,590.00 |
| PhiloMetron, Inc | Weight Management System | $ 60,216.00 | $ 106,989.00 |
| PhiloMetron, Inc. | Integrated Vascular Access stenosis Mitigation System | $ 27,258.50 | $ 74,813.50 |
| Phoenix Biosystem Inc | Rapid POC STD Molecular Diagnostics | $ 143,760.00 | $ 100,719.25 |
| PhotoThera, Inc. | NeuroThera Laser System and TLT for the Treatment of Acute Ischemic Stroke | $ 244,479.25 | |
| PIKAMAB Inc | Development and Commercialization of ADCC Therasight™. | $ 244,479.25 | |
| PIKAMAB, Inc. | Development and Commercialization of Lupus Therasight | $ 244,479.25 | |
| Piper Medical dba Odyssey Medical Technologies | Portable, battery operated, low cost (<$500), Tactical CO2 Asthma and COPD Respiratory Therapy Device | $ 22,262.00 | $ 11,975.00 |
| Piper Medical dba Odyssey Medical Technologies | Quixie Cancer Drug Inhalation Therapy | $ 8,415.50 | $ 9,547.50 |
| Planet Biotechnology Inc | TEM-8Fc, An Anti-Cancer Immunoadhesin Made in Plants | $ 13,948.50 | $ 16,850.00 |
| Planet Biotechnology Inc | PBI-220 A Novel Therapy for Inhalational Anthrax | $ 244,479.24 | |
| Planet Biotechnology Inc | PBI-230, a therapy for treatment of botulism | $ 135,834.50 | $ 108,644.74 |
| PlenSat, Inc. | Digestible Balloon Obesity Treatment | $ 216,951.50 | $ 27,527.74 |
| Plexxikon Inc | Small molecule inhibitors of CRAF kinase for the treatment of polycystic kidney disease | $ 244,479.25 | |
| Plexxikon Inc. | Small molecule inhibitors of Fms receptor tyrosine kinase for the treatment of cancers | $ 244,479.25 | |
| Plexxikon Inc. | Small molecule inhibitors of BRAF kinase for treatment of cancers | $ 244,479.25 | |
| PneumRx, Inc. | RePneu ® Lung Volume Reduction Coil (LVRC) System | $ 244,479.24 | |
| Poincare Systems Inc | AccuSwept MIS Surgical Device | $ 97,673.50 | |
| Portaero, Inc. | Trans-Thoracic Wall Assisted Therapeutic Drug Administration for Emphysema | $ 244,479.25 | |
| Portola Pharmaceuticals Inc | Elinogrel - Novel direct-acting competitive reversible P2Y12 inhilitor | $ 244,479.25 | |
| Portola Pharmaceuticals Inc | PRT061103 | $ 244,479.25 | |
| Portola Pharmaceuticals, Inc | PRT062607-Novel, oral Syk-specific inhibitor | $ 244,479.25 | |
| Portola Pharmaceuticals, Inc | Betrixaban-Novel, oral, direct, Factor Xa inhibitor | $ 244,479.25 | |
| Portola Pharmaceuticals, Inc | PRT062070 - Novel, oral Syk-Jak kinase inhibitor | $ 36,720.50 | $ 207,758.75 |
| Portola Pharmaceuticals, Inc. | PRT064445 - Universal Factor Xa Antidote | $ 244,479.25 | |
| Posit Science Corporation | Plasticity-based Adaptive Cognitive Remedation (PACR) | $ 244,479.25 | |
| Praevium Research Inc | Ultra-High Speed and Ultra-broadband Sources for Optical Coherence Tomography | $ 148,096.50 | $ 71,230.50 |
| Precise Light Surgical | Acute Ischemic Stroke treatment with localized tPA delivery | $ 29,710.00 | $ 214,769.25 |
| Prediction Sciences LLC | Theranostic for ischemic stroke | $ 244,479.24 | |
| PRESIDIO PHARMACEUTICALS, INC | NS5B | $ 244,479.25 | |
| PRESIDIO PHARMACEUTICALS,INC | NS5A | $ 244,479.25 | |
| Proacta | HSMKI development program | $ 244,479.24 | |
| Proacta, Inc. | PR104 development program | $ 244,479.24 | |
| Probactive Biotech, Inc | Antibody targeted Liposomal Etoposide (provisionally referred as "ATLE") | $ 242,539.52 | $ 1,939.72 |
| Probactive Biotech, Inc. | Radioimmunotherapy (RIT) Iodine - 131 Antinuclear Antibody (ANA) | $ 244,479.24 | |
| Prodo Laboratories Inc. | Human Islet Expansion | $ 141,723.83 | $ 102,755.42 |
| Prodo Laboratories Inc. | Human Islets For Research Resourcing & Distribution | $ 134,137.63 | $ 110,341.62 |
| Progentech-USA, Inc. | Progentech Integrated Molecular Diagnostic System | $ 244,479.25 | |
| Prognosys Biosciences Inc | Technology for Mapping Protease Activity Across the Proteome | $ 16,693.50 | $ 68,236.50 |
| Prognosys Biosciences, Inc. | Technology for Multiplexed Profiling of Protease Activity | $ 103,875.50 | |
| Prognosys Biosciences, Inc. | Technology for Mapping Protein Kinase Activity Across the Proteome | $ 66,428.50 | |
| Prolynx LLC | Macromolecule-Drug Conjugate Delivery Platform | $ 65,330.00 | $ 179,149.24 |
| ProSci Inc | Novel HIV/AIDS Vaccine Project | $ 244,479.25 | |
| Prosetta Bioconformatics Inc | BioConformatics | $ 149,267.91 | $ 95,211.34 |
| Prosetta Bioconformatics, Inc | Anti-Virals | $ 244,479.25 | |
| PROTELIX, INC. d/b/a PROTELICA | A universal bioinformatics based Antibody Mimic Platform for the Discovery and Development of Novel Therapeutics | $ 244,479.25 | |
| Proteus Biomedical, Inc. | Chipskin Technology | $ 244,479.25 | |
| Proteus Biomedical, Inc. | The Raisin system | $ 244,479.25 | |
| Protigen Inc | Development of Nephrilin for the treatment of diabetic complications and cancer | $ 126,311.00 | $ 118,168.24 |
| Proveri Inc. | Prostate Cancer Diagnostics and Prognostics | $ 74,967.50 | $ 169,511.74 |
| Providence Medical Technology, Inc | DTRAX Delivery System | $ 244,479.24 | |
| Psylin Neurosciences Inc | Peptid Therapeutics for the treatment of Schizophrenia | $ 244,479.25 | |
| PSYLIN NEUROSCIENCES, INC. | Peptide therapeutics for the treatment of depression | $ 244,479.24 | |
| PULMONX INC | Chartis Pulmonary Assessment System and Zephyr Endobronchial Valve for Emphysema | $ 244,479.25 | |
| QLT Plug Delivery Inc | Novel Punctal Plug Sustained Release Drug Delivery System - Opthalmics | $ 244,479.24 | |
| QUALIGEN INC | ALPHA GST | $ 31,531.00 | $ 182,238.50 |
| QuantaLife, Inc. | Rapid low-cost MRSA diagnostics | $ 244,479.25 | |
| Quark Pharmaceuticals, Inc | QPI-1007 for non-arteritic ischemic optic neuropathy (NAION) | $ 244,479.24 | |
| Quark Pharmaceuticals, Inc | QPI-1002 (I5NP) for Delayed Graft Function (DGF) in Kidney Transplant | $ 244,479.24 | |
| Quark Pharmaceuticals, Inc. | QPI-1002 (I5NP) for Acute Kidney Injury (AKI) | $ 244,479.24 | |
| Quexta, Inc | Low inventory, low cost eyeglasses | $ 80,950.50 | $ 93,750.00 |
| Quiescence Medical, Inc | Pharyngeal Stent to Treat Sleep Apnea | $ 53,200.00 | $ 191,279.25 |
| RadioRx, Inc | RRx-001 | $ 244,479.25 | |
| Raptor Discoveries Inc | WntTide, a peptide targeting LRP6 positive breast cancers | $ 83,078.00 | $ 137,450.00 |
| Raptor Discoveries Inc. | HepTide, a drug targeting peptide for the potential treatment of liver disease | $ 111,027.00 | $ 7,500.00 |
| Raptor Therapeutics Inc | DR Cysteamine for the potenial treatment of Huntington's Disease | $ 220,167.50 | $ 24,311.75 |
| Raptor Therapeutics Inc | DR Cysteamine for the potenial treatment of non-alocholic steatohepatitis (NASH) | $ 215,299.50 | $ 29,179.75 |
| Raptor Therapeutics Inc | DR Cysteamine for the potenial treatment of Cystinosis | $ 244,479.25 | |
| Receptos Inc | Inhibition of lung inflammation associated with influenza viral infection | $ 160,570.00 | $ 83,909.25 |
| Receptos Inc | Small Molecule GLP1R Agonist Program | $ 103,397.00 | $ 141,082.25 |
| Reduction Technologies Inc. | Novel Therapy for the Non-Fusion Treatment of Adolescent Idiopathic Scoliosis | $ 210,119.36 | $ 34,359.89 |
| Redwood Bioscience Inc | Universal Carrier Scaffolds for Drug Delivery | $ 58,352.96 | $ 186,126.28 |
| Regulus Therapeutics Inc | Novel microRNA therapeutics for treatment of hepatitis C viral infection | $ 244,479.25 | |
| Regulus Therapeutics, Inc | Novel microRNA therapeutics for treatment of fibrosis | $ 244,479.25 | |
| Relevare Pharmaceuticals Inc | Combination therapy for the treatment of chronic neuropathic pain conditions | $ 244,479.25 | |
| Relia Diagnostic Systems, Inc | Relia Diagnostic Systems, Inc | $ 244,479.25 | |
| Relypsa, Inc. | RLY 106 polymer bile acid sequestrant ("BAS") for lowering cholesterol and glucose levels | $ 244,479.24 | |
| Relypsa, Inc. | RLY 5016 Potassimum Management | $ 244,479.24 | |
| Renova Therapeutics, Inc | Gene Therapy Transfer for Clinical Congestive Heart Failure | $ 119,388.50 | $ 125,090.75 |
| Renovorx | An Endovascular Catheter for Targeted Delivery of Drug/Cells to the Pancreas | $ 6,250.00 | $ 22,750.00 |
| Replenish Inc | Implantable Anterior MicroPump System for Glaucoma | $ 244,479.25 | |
| Replenish Inc | Implantable Ophthalmic MicroPump for Retina Drug injections | $ 244,479.25 | |
| Resolution Biomedical Inc. | ClearPrep Cytology Solution and Test Kit | $ 25,106.07 | $ 219,373.18 |
| Response Genetics Inc | Genetic Profile Product Development | $ 244,479.25 | |
| Retina Pharma Inc | To develop an Anti -Angiogenic Therapeutic for Wet Age related Macular Degeneration (AMD). | $ 244,479.25 | |
| RetroVirox, Inc | Novel therapies for the treatment of HIV infection | $ 35,914.69 | $ 171,794.75 |
| REVA Medical Inc | Peripheral Biodegradabe Drug Delivery Stent | $ 244,479.25 | |
| REVA Medical, Inc | REVA's Bioresorbable Drug-Eluting Stent | $ 244,479.25 | |
| REVA Medical, Inc. | Structural Alloplastic Bone Graft (SABG) | $ 127,415.50 | $ 29,161.00 |
| REVA Medical, Inc. | Bioresorbable, Radiopaque Embolic Microspheres (BREMS) | $ 60,250.00 | $ 8,357.50 |
| Revance Therapeutics, Inc. | RT001 Topical Botulinum Toxin A for Plantar Fasciitis | $ 244,479.25 | |
| Revascular Therapeutics Inc | Revascular Chronic Total Occulusion System | $ 244,479.25 | |
| Reverse Medical Corporation | ACUTE STROKE INFUSION THROMBECTOMY CATHETER PROJECT | $ 244,479.24 | |
| ReVision Therapeutics Inc | Development of Fenretinide for the Treatment of age-related macular Degeneration | $ 244,479.24 | |
| REVIVA PHARMACEUTICALS INC | RP5000 PROGRAM FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS | $ 146,982.00 | $ 97,497.25 |
| Ridge Diagnostics, Inc. | Blood-based tests for the diagnosis and monitoring of Neuropsychiatric disorders | $ 211,457.00 | $ 33,022.24 |
| Rigel Pharmaceuticals Inc | Syk Inhibitors with Improved Specificity for the Treatment of Rheumatoid Arthritis | $ 244,479.25 | |
| Rigel Pharmaceuticals Inc | Janus Kinase 2(JAK2) Inhibitor for the Treatment of Myeloproliferative Neoplasms | $ 165,761.00 | $ 65,927.00 |
| Rigel Pharmaceuticals Inc | PKC-theta inhibitors for the Treatment of Multiple Sclerosis | $ 244,479.25 | |
| RIGEL PHARMACEUTICALS INC | Adiponectin Mimetics for the Treatment of Type 2 Diabetes | $ 244,479.25 | |
| Rigel Pharmaceuticals, Inc | Spleen tyrosine kinase (Syk) Inhibitors for Treating Non-Hodgkins Lymphoma | $ 244,479.25 | |
| Rigel Pharmaceuticals, Inc | JanUS Kinase 1/3 inhibitors for the Treatment and Prevention of Organ Transplant Rejection | $ 244,479.25 | |
| Rigel Pharmaceuticals, Inc. | Inhibitors of Axl Kinase for the Treatment of Metastatic Disease | $ 164,647.00 | $ 8,356.50 |
| Rigel Pharmaceuticals, Inc. | Novel Treatments for Muscle Wasting | $ 244,479.25 | |
| Rigel Pharmaceuticals, Inc. | Fostamatinib disodium (FosD), an oral syk inhibitor for treating Rheumatiod Arthritis (RA) | $ 244,479.25 | |
| Rigel Pharmaceuticals, Inc. | Topical JAK 1/3 Inhibitors for the Treatment of Psoriasis | $ 91,784.00 | $ 152,695.25 |
| Ritter Pharmaceuticals, Inc. | RP-G28 A Novel Treatment of Lactose Intolerance | $ 244,479.25 | |
| Roxro Pharma, Inc | SPRIX | $ 244,479.24 | |
| Ruga Corporation | Targeted Cancer drug for Multiple Myeloma | $ 108,990.00 | |
| RUGA Corporation | Cancer treatment targeting glucose metabolism | $ 244,479.25 | |
| Sadra Medical Inc. | LotusTM Valve System for transcutaneous aortic valve replacement therapy | $ 244,479.25 | |
| SafeLife Corp | Antimicrobial Catheters | $ 194,891.50 | $ 49,587.75 |
| SafeLife Corp. | Antimicrobial Respirator | $ 244,479.25 | |
| SanBio, Inc. | SB623 Cell Therapy for the Recovery of Function from Disability Caused by Ischemic Stroke | $ 244,479.25 | |
| Sangamo BioScience, Inc. | SB-313-xTZ for Recurrent or Refractory Glioblastoma Multiforme (GBM) | $ 244,479.25 | |
| Sangamo BioSciences, Inc | SB-728-T for Human Immunodeficiency Virus/Acquired immunodeficiency Syndrome (HIV/AIDS) | $ 244,479.25 | |
| Sangamo BioSciences, Inc. | SB-509 for Diabetic Peripheral Neuropathy(DPN) | $ 244,479.25 | |
| Sangamo BioSciences, Inc. | SB-509 for Amyotrophic Lateral Sclerosis (ALS) | $ 244,479.25 | |
| Sanovas, Inc. | Sanovas Interventional Drug Therapy | $ 244,479.25 | |
| SanRx Pharmaceuticals Inc | Dipterinyl Calcium Pentahydrate (DCP) | $ 14,847.50 | $ 229,631.74 |
| Sapheon Inc | Sapheon Closure System | $ 244,479.24 | |
| SARCODE CORPORATION | SARcode SAR 1118 Ophthalmic Solution | $ 244,479.25 | |
| Satiety, Inc | TOGA | $ 244,479.25 | |
| Satiogen Pharmaceuticals Inc | Colon/Rectum targeted GPBAR1 agonists for the treatment of obesity | $ 51,039.00 | $ 50,829.00 |
| SATIOGEN PHARMACEUTICALS, INC | AN ORAL, SMALL MOLECULE INHIBITOR OF THE ASBT FOR THE TREATMENT OF OBESITY | $ 114,216.00 | $ 71,488.00 |
| SBIO Inc. | SBIO SB1518 JAK2/FLK3 Inhibitor | $ 244,479.24 | |
| Scharp Technologies, Inc | Burn and Wound Dressing Treatment | $ 244,479.25 | |
| SciClone Pharmaceuticals, Inc | SciClone Oral Mucositis | $ 244,479.25 | |
| SciClone Pharmaceuticals, Inc | SciClone Hepatitis C | $ 244,479.25 | |
| SciClone Pharmaceuticals, Inc. | SciClone Vaccine Enhancer | $ 221,306.50 | $ 23,172.75 |
| SciClone Pharmaceuticals, Inc. | SciClone Oncology | $ 244,479.25 | |
| SCIGENE CORPORATION | Automated genetic analysis system for human disease | $ 216,842.50 | $ 27,636.74 |
| SCRIPPS LABORATORIES, INC. | DIABETES - LOW COST HEMOGLOBIN A1C METER AND TEST | $ 244,479.24 | |
| SeaChange Pharmaceuticals, Inc | Drug Repurposing using Chemoinformatic Links | $ 48,051.61 | |
| Sechrist Industries Inc | Technological Advancements | $ 172,045.00 | $ 72,434.25 |
| Sechrist Industries Inc | Utility of Large Hyperbaric Chamber | $ 203,864.00 | |
| SEKRIS Corporation | Pro-Apoptotic DNA Vaccination for the treatment of type 1 diabetes | $ 244,479.25 | |
| Selby Life Science LP | Antiangiogenic Surrobodies ™ for the treatment of multiple cancers | $ 208,891.58 | $ 35,587.67 |
| Selby Life Sciences LP | Surrobodies [tm] for the treatment of Multiple Solid Tumor Cancers | $ 219,832.84 | $ 24,646.41 |
| Selby Life Sciences, LP | Surrobodies TM for the Treatment of Breast and Other Cancer | $ 244,479.25 | |
| Selby Life Sciences, LP | Passive Immunity and Therapeutic Treatment of Seasonal Influenza | $ 106,735.67 | $ 137,743.58 |
| Selby Life Sciences, LP | Proapoptotic Surrobodies™ for the Treatment of Multiple Cancers | $ 222,872.70 | $ 21,606.54 |
| Selby Life Sciences, LP | Surrobodies ™ for the Treatment of Diabetes and Obesity | $ 196,036.18 | $ 48,443.07 |
| Selexagen Therapeutics, Inc | Hedgehog Pathway Inhibitor for the Treatment of Cancer | $ 27,108.48 | $ 217,370.77 |
| Selexagen Therapeutics, Inc. | Oncogenic BRAF Kinase (V600E) Inhibitor for the treatment of cancer | $ 2,087.29 | $ 242,391.96 |
| Senomyx, Inc. | Sweet Enhancer Program | $ 244,479.25 | |
| Sensor Innovations, Incorporated (DBA Sensorin) | Improved diabetes therapeutics administration via novel self-calibrating glucose sensor | $ 244,479.24 | |
| SentreHEART, Inc | PLACE: Permanent Left Auricular Closure & Exclusion in Patients with Atrial Fibrillation | $ 244,479.24 | |
| Sequel Pharmaceuticals, Inc | K201: a novel treatment for Atrial fibrillation | $ 244,479.25 | |
| Sequenom, Inc | Age-related macular degeneration test | $ 244,479.25 | |
| SEQUENOM, INC. | PRENATAL TESTING FOR TRISOMY 21 (DOWNSYNDROME) | $ 244,479.25 | |
| Sequent Medical Inc | Woven EndoBridge Cerebral Aneurysm Embolization Device (WEB) | $ 244,479.25 | |
| Sialix Inc (formerly Gc-Free Inc) | N-glycolyneuraminic Acid in the Pathogenesis and Progression of Rheumatoid Arthritis | $ 6,376.00 | $ 59,123.50 |
| Sialix Inc (formerly Gc-Free Inc) | Detection of Non-Human Sialic Acid in Biotherapeutic Applications | $ 52,127.50 | $ 42,714.50 |
| Sialix, Inc (formerly Gc-Free,Inc.) | Neu5Gc-Glycan Arrays for Discovery and Validation of Human Cancer Biomarkers | $ 28,370.50 | $ 86,694.50 |
| Sierra Surgical Technologies Inc. | Minimally Invasive System | $ 244,479.24 | |
| Silk Road Medical Inc | FAST-CAS(Flow Altered Short Transcervical Carotid Artery Stenting) Research/Development | $ 244,479.24 | |
| Silver Lake Research Corporation | Rapid Diagnostic Test Kit for Urinary Tract Infections | $ 73,817.51 | $ 145,222.90 |
| Silver Lake Research Corporation | Development of Rapid Diagnostic test Kit for Methicillin-Resistant Staph. Aureus | $ 53,665.12 | |
| Silver Lake Research Corporation | EAP-Derived Monoclonal Antibodies for Cancer Diagnostics by Immunohistochemistry | $ 23,802.44 | $ 31,071.09 |
| Silver Medical, Inc. | Intra-operative monitoring of stroke in high-risk patient populations | $ 10,868.50 | $ 135,500.00 |
| Solulink, Inc | Highly multiplexed cancer biomarker assays. | $ 41,622.00 | $ 155,749.50 |
| SomaGenics, Inc | An RNA-based therapeutic for hepatitis C | $ 244,479.25 | |
| SomaGenics, Inc. | miR-ID, a novel diagnostic platform for microRNAs and other small RNAs | $ 76,535.82 | $ 25,904.69 |
| Somaxon Pharmaceuticals, Inc. | Silenor (doxepin hydrochloride), a pharmaceutical treatment for insomnia | $ 244,479.25 | |
| Sonexa Therapeutics, Inc. | ST101 Compound for Alzheimer's Disease | $ 244,479.24 | |
| Sorbent Therapeutics Inc | CLP(Cross Linked Polyelectorlyte) | $ 244,479.24 | |
| Sorrento Therapeutics, Inc | STI-MRSV | $ 150,000.00 | |
| Sorrento Therapeutics, Inc. | STI-MRSA | $ 195,089.50 | $ 49,389.74 |
| Sotera Wireless, Inc. | ViSiMobile System | $ 244,479.24 | |
| Specialized Vascular Technologies, Inc | EndoCoat Drug-Eluting Stent | $ 244,479.24 | |
| Spectral Molecular Imaging, Inc | Early Melanoma Detection Device Using Hyperspectral Imaging | $ 32,622.00 | $ 157,550.00 |
| SpectraScience Inc | WavSTAT Optical Biopsy System-Inflammatory Bowel Disease-Cancer | $ 202,308.50 | |
| SpectraScience, Inc | WavSTAT optical Biopsy System - Esophageal Cancer | $ 244,479.24 | |
| SpectraScience, Inc. | LUMA Cervical Imaging System - FDA Post Approval Study | $ 73,480.00 | $ 41,731.00 |
| SPECTROS CORPORATION | NON-INVASIVE, TRANS-ABDOMINAL BROADBAND OXIMETER FOR EARLY-STAGE NEC DIAGNOSIS | $ 79,006.00 | $ 108,375.00 |
| Spectros Corporation | Real-Time Detection of Colon Ischemia During Abdominal Aortic Aneurysm Surgery | $ 76,988.00 | $ 55,908.50 |
| Spectros Corporation | ProstaFluor FDA Trail for Real-Time Margin Detection During Protatectomy | $ 39,409.00 | $ 205,070.24 |
| Spectros Corporation | Broadband Spectroscopic Localization of Breast Cancer | $ 244,479.24 | |
| Spectrum Pharmaceuticals Inc | Renazorb | $ 244,479.25 | |
| Spectrum Pharmaceuticals Inc | Zevalin | $ 244,479.25 | |
| Spectrum Pharmaceuticals, Inc. | Apaziquone | $ 244,479.25 | |
| Spectrum Pharmaceuticals,Inc. | Belinostat, a novel anti-cancer agent | $ 244,479.25 | |
| SpinalMotion, Inc | Artificial Spinal Discs to Treat Back Pain More Effectively at Lower Cost that Spinal Fusion | $ 244,479.24 | |
| SpineAlign Medical Inc | VerteLift | $ 244,479.25 | |
| Spiracur Inc | SNaP | $ 244,479.24 | |
| Stategics, Inc | Small molecule erythropoietin mimetics for the treatment of neurological disorders | $ 28,629.82 | $ 23,433.34 |
| Stellar Biotechnologies, Inc | Diagnostic Immune Status Monitoring in Patients with Immunodeficiency | $ 244,479.24 | |
| STELLAR BIOTECHNOLOGIES, INC. | ENABLING ICH-S8 IMMUNOTOXICITY TESTING WITH KEYHOLE LIMPET HEMOCYANIN | $ 244,479.25 | |
| Stem CentRx, LLC | Identification and Therapeutic of Solid Tumor Cancer Stem Cells | $ 244,479.25 | |
| StemCells California Inc | HuCNS-SC Eye | $ 244,479.25 | |
| StemCells California, Inc. | HuCNS-SC Spinal Cord Injury | $ 244,479.25 | |
| StemCells California, Inc. | hLEC Project | $ 244,479.25 | |
| StemCells California, Inc. | HuCNS-SC Brain | $ 244,479.25 | |
| Stemcyte Inc | Chronic Spinal Cord Injury Treatment | $ 244,479.25 | |
| Stemcyte, Inc. | Chronic Stroke | $ 157,177.50 | $ 87,301.75 |
| Stemedica Cell Technologies, Inc. | Allogenic Mesenchymal Stem Cell Therapy Stroke in the USA | $ 244,479.25 | |
| Stephen J Peroutka MD PhD | Opioid Dose Reduction Taper Pack Device | $ 4,805.00 | $ 120,100.10 |
| STKR, Inc. | STKR QwikJect | $ 143,516.50 | $ 100,962.75 |
| String Therapeutics Inc | Creation of safe and effective PAP for development of immunotoxin for lupus | $ 175,000.00 | |
| String Therapeutics Inc | Direct Intracranial administration of BMP-4 as Therapy Against Giloblastoma | $ 220,000.00 | |
| Stroma Medical Corporation | Iris Stroma Retraction and Depigmentation | $ 106,917.10 | $ 137,562.15 |
| Sunesis Pharmaceuticals, Inc | Development of voreloxin for the treatment of patients with acute myeloid leukemia | $ 244,479.24 | |
| Suneva Medical, Inc. | Artefill for the Treatment of HIV-Associated Lipoatropy | $ 2,000.00 | $ 242,479.25 |
| SuperGen Inc | SGI-1776-PIM Kinase Inhibitor (an anti-cancer compound) | $ 244,479.25 | |
| Sutro Biopharma, Inc | Commercial Scale Cell-Free Production Enabling Novel Neutropenia Therapies | $ 244,479.25 | |
| SuviCa Inc. | Lead optimization and biomarker identification for novel anti-cancer therapies | $ 102,500.00 | |
| Symor, Inc | Symthetic TGF-beta ligands for bone repair and diseases | $ 244,479.24 | |
| Synedgen, Inc | Novel Therapeutics to Treat Bacterial Infections including Drug Resistant Bacteria | $ 218,735.00 | $ 25,744.24 |
| Synergenesis Inc | MNC-1000 | $ 20,964.71 | $ 81,703.77 |
| Synosia Therapeutics, Inc | Clinical development of SYN115: a new chemical entity for treating Parkinson's Disease (PD) | $ 244,479.25 | |
| Synosia Therapeutics, Inc. | Clinical development of SYN120: a new treatment for Alzheimer's disease (AD) | $ 244,479.25 | |
| Synthasome Inc | Therapeutic Delivery for Tendon Repair | $ 244,479.25 | |
| T F Instruments | Phase X-ray Diagnostic Imaging | $ 222,000.00 | |
| Tacere Therapeutics, Inc. | Ocular (SMK-01/03) | $ 244,479.25 | |
| Tacere Therapeutics, Inc. | Hepatitis C (TT-034) | $ 244,479.25 | |
| TaiMed Biologics USA | Tamiphosphor for influenza infections | $ 28,738.00 | $ 54,213.50 |
| TaiMed Biologics USA | Ibalizumab for HIV-1 infections | $ 244,479.24 | |
| Talima Therapeutics, Inc | Terbinafine Micro Implant (TMI-358) | $ 244,479.25 | |
| Tandem Diabetes Care Inc. | T-Slim Infusion Pump - Diabetes | $ 244,479.24 | |
| Tandem Diagnostics, Inc | Non-invasive prenatal diagnosis of fetal genetic abnormalities | $ 111,484.38 | $ 132,994.86 |
| Taraxos, Inc. | Novel Topical Analgesic for Peripheral Neuropathy | $ 39,623.11 | $ 57,500.00 |
| Targeson Inc. | Diagnostic Test for Crohn's Disease | $ 112,793.00 | $ 131,686.25 |
| TARGETED MEDICAL PHARMA, INC | Novel Treatment for Sleep Disorders in the Elderly | $ 244,479.25 | |
| TARGETED MEDICAL PHARMA, INC | NEW THERAPY TO REDUCE SIDE EFFECTS OF PAIN DRUGS | $ 244,479.25 | |
| TARGETED MEDICAL PHARMA, INC. | A safe and effective treatment for Gulf War illness | $ 244,479.25 | |
| Telik, Inc | Phase 2 Randomized Clinical Trial of Telintra for Treatment of Severe Chronic Neutropenia. | $ 208,368.00 | $ 36,111.24 |
| Telik, Inc | Phase 2 Clinical trial of Telcyta for the treatment of Refractory Lymphoma & Multiple Myeloma | $ 244,479.24 | |
| Telik, Inc. | Phase2 Clinical Trial of Telintra ® in Low to Intermediate-1 Risk Myelodysplastic Syndrome | $ 244,479.24 | |
| Telik, Inc. | Clinical Trial of Telintra® & Revlimid® in Patients with Myelodysplastic Sydrome (MDS). | $ 213,536.50 | $ 30,942.74 |
| Telik, Inc. | Development of a Novel Inhibitor of Aurora and VEGFR Kinases for the Treatment of Cancer. | $ 244,479.24 | |
| Tethys Bioscience Inc | Cardiovascular Event Prevention | $ 244,479.25 | |
| Tethys Bioscience, Inc. | PreDx Diabetes Risk Score | $ 244,479.25 | |
| Tethys Bioscience, Inc. | Diagnostics for the Prevention and Management of Cardiometabolic Disease | $ 142,933.00 | |
| TheraCell Inc. | Stem Cell Separation and Gene Transfection Device' | $ 137,527.00 | $ 106,952.25 |
| THERACOS INC | THR-1442 | $ 244,479.24 | |
| Theracos, Inc | THR-4450 | $ 244,479.24 | |
| Therapeutics Clinical Research, A Medical Corporation | Carbazole | $ 11,551.92 | $ 175,760.76 |
| Therapeutics Clinical Research, A Medical Corporation | Super-Potent Corticosteroid Lotion | $ 49,392.00 | $ 195,087.25 |
| Therapheresis, Inc | TheraSystem I | $ 130,545.00 | $ 113,934.25 |
| Theravance Inc | A novel approach to the management of congestive heart failure | $ 244,479.24 | |
| Theravance Inc | Improving the quality of life for patients with opioid-induced constipation | $ 244,479.24 | |
| Theravance Inc | A novel approach to the management of uncontrolled hyper tension | $ 244,479.24 | |
| Theravance Inv | Novel symptomatic and disease approach to the treatment of Alzheimer's Disease | $ 244,479.24 | |
| Theravance, Inc | A novel treatment designed to cure Hepatitis C and prevent hepatocellular carcinoma | $ 244,479.24 | |
| Theravance, Inc | Novel bifunctional muscarinic antagaonist-beta2 agonist for respiratory disorders | $ 219,000.00 | $ 25,479.24 |
| Theravance, Inc | A novel oral therapy for the treatment of pulmonary arterial hypertension | $ 244,479.24 | |
| Theravance, Inc | A novel lung-selective muscarinic antagonist for chronic obstructive pulmonary disease | $ 244,479.24 | |
| Theravance, Inc | A Novel analgesic optimized to reduce or replace opioid-based therapies for chronic pain | $ 244,479.24 | |
| Theravance, Inc. | Novel approach to the treatment of resistant Gram-positive bacterial infections | $ 244,479.24 | |
| Theravance, Inc. | Novel approaches for the tratment of Gram-negative bacterial infections | $ 244,479.24 | |
| THERAVIDA INC | THVD-102 | $ 244,479.25 | |
| Theregen Inc. | Clinical development of Anginera™ for the Treatment of Refractory Angina/Ischemia | $ 244,479.25 | |
| Therinject LLC | Sustained Release Anti-Cancer Immuno-therapeutic Formulation Development | $ 32,596.00 | $ 7,664.00 |
| Thermogenesis Corp. | Res-Q 60 BMA | $ 244,479.25 | |
| TherOx, Inc. | SSO2 Therapy for the Treatment of Heart Attack | $ 244,479.24 | |
| Threshold Pharmaceuticals Inc | Hypoxia-Activated prodrug technology plaform for cancer drug discovery and development | $ 244,479.25 | |
| Threshold Pharmaceuticals, Inc. | Clinical Development of Hypoxia Activated Prodrug TH-302 for the Treatment of Cancer | $ 244,479.24 | |
| Tioga Pharmaceuticals, Inc | Asimadoline for the Treatment of Irritable Bowel Syndrome | $ 244,479.24 | |
| TLC Biopharmaceuticals, Inc. | Lipotecan® TLC388 Anti-Tumor Therapeutic | $ 241,979.50 | $ 2,499.74 |
| TM3 Therapeutics LLC | A novel method of generating Therapeutic HIV vaccines | $ 39,844.50 | $ 204,634.75 |
| TM3 Therapeutics LLC | A respiratory prophylactic vaccine | $ 29,883.50 | $ 195,422.00 |
| TM3 Therapeutics LLC | A novel method of generating fully human monoclonal antibody therapeutics | $ 29,883.50 | $ 158,500.00 |
| Tocagen Inc. | Toca 511 with 5-FC to Significantly Improve Glioblastoma Multiforme Camcer Patient Survival | $ 244,479.24 | |
| Topica Pharmaceuticals, Inc | Development of a Novel Antifungal, Luliconazole, for Onychomycosis | $ 244,479.25 | |
| Tosk, Inc | TK-112690 for the Prevention of Cancer Chemotherapy Induced Mucositis | $ 244,479.24 | |
| Tosk, Inc. | TK-115339 for the Prevention of Chemotherapy Induced Cardiotoxicity | $ 95,220.35 | $ 149,258.90 |
| Tragara Pharmaceuticals Inc | Capoxigem (apricoxib, TG01) an Oral COX-2 Inhibitor for the Treatment of Cancer | $ 244,479.24 | |
| Tragara Pharmaceuticals, Inc | TG02, an Oral Multi-kinase Inhibitor for the Treatment of Cancer | $ 244,479.24 | |
| Transcend Medical Inc | Drug-Eluting Microstent for Glaucoma Treatment | $ 244,479.25 | |
| Transcept Pharma, Inc | INTERMEZZO | $ 244,479.25 | |
| Transdel Pharmaceuticals, Inc. | Efficacy and Safety of Ketoprofen Cream in the Treatment of Acute Pain | $ 244,479.25 | |
| Transpose Medical LLC | UGIB Therapy | $ 147,550.00 | |
| Transvivo, Inc. | OMNI-OA | $ 244,479.25 | |
| Traversa Therapeutics, Inc | Development of the PTD-DRBD delivery technology for siRNA drug therapies | $ 244,479.25 | |
| Traversa Therapeutics, Inc | Development of RNA interference-based drug candidates for human brain cancer | $ 243,868.00 | $ 611.25 |
| Trellis Bioscience, LLC | Development of a human-derived antobody to prevent maternal-fetal transmission of CMV | $ 244,479.25 | |
| Trellis Bioscience, LLC | Development of a human-derived antibody for pandemic influenza with broad strain efficacy | $ 244,479.25 | |
| TriAct Therapeutics, Inc. | TT-100 | $ 222,500.00 | |
| Trillium Engineering Inc | Image-guided Liver Tumor Ablation using Internal Energy (Vapor) | $ 34,517.50 | $ 82,500.00 |
| Trius Therapeutics, Inc. | Torezolid research & Development | $ 244,479.24 | |
| TriVascular, Inc | TriVascular's Ovation™ Abdominal Stent Graft System(Ovation ™ /ASGS) | $ 244,479.25 | |
| TriVascular, Inc. | TriVascular's Thoracic Stent-Graft System | $ 244,479.25 | |
| Ultrawave Labs | UltraWave Imaging Technology | $ 62,747.49 | $ 181,731.75 |
| Universal Stabilization Technologies Inc | Thermostable Rabies Vaccines for Oral Delivery | $ 61,365.00 | $ 131,694.00 |
| Universal Stabilization Technologies Inc. | Thermostable Measles Vaccines for Pulmonary Delivery | $ 28,750.00 | |
| US Biotest, Inc | Progenitor Cell Engrafment | $ 129,384.10 | $ 115,095.14 |
| US Biotest, Inc | Treatment of Multiple-Cytopenias with TXA127 | $ 244,479.24 | |
| US Biotest, Inc | Treatment of Acute Respiratory Distress Syndrome with TXA127. | $ 214,005.55 | |
| USGI Medical, Inc | Development of Incisionless Operating Platform and procedure for the treatment of obesity | $ 244,479.25 | |
| Valent Technologies LLC | VAL-083 | $ 12,579.50 | $ 231,899.74 |
| Valentx, Inc | ENDO BYPASS SYSTEM | $ 244,479.25 | |
| Vascular Biosciences | CAR Peptide for Targeted Drug Delivery | $ 66,876.00 | $ 115,000.00 |
| Vascular Designs, Inc. | IsoFlow Ainfusion Catheter | $ 158,850.50 | $ 85,628.75 |
| Vascular Imaging Corporation | Intravascular ultrasound steerable imaging guidewire | $ 244,479.24 | |
| VasoNova, Inc. | VasoNova-VPS | $ 244,479.25 | |
| Vaxart Inc | Pediatric formulation for oral vaccines | $ 38,704.50 | $ 88,505.00 |
| Vaxart Inc | Vaccine for Venezeulan equine encephalitis | $ 157,061.00 | $ 87,418.25 |
| Vaxart Inc | Vaccine for Herpes Simplex Virus type 2 | $ 16,366.00 | |
| Vaxart Inc | Vaccine to prevent pandemic avian influenza | $ 92,701.50 | $ 151,777.75 |
| Vaxart Inc | Oral-delivery vaccine for seasonal influenza | $ 42,823.00 | $ 41,095.00 |
| Vaxiion Therapeutics, Inc. | Commercialization of a novel, minicell-based, nano-sized targeted drug and RNAi delivery platform technology | $ 117,783.00 | $ 126,696.24 |
| Velomedix Inc | Novel Automated Peritoneal Lavage System for Controlled Induction of Therapeutic Hypothermia | $ 244,479.25 | |
| VentiRx Pharmaceuticals Inc | TLR8 Agonist (VTX-2337): Targeted Novel Immunotherapy for Multiple Oncology Indications | $ 244,479.24 | |
| VentiRx Pharmaceuticals, Inc. | TLR8 Agonist (VTX-1463): Novel Immunomodulatory Agent for Allergic Rhinitis and Asthma | $ 244,479.24 | |
| Veracyte, Inc | Molecular profiling of thyroid nodules to determine benign or malignant cancer | $ 244,479.25 | |
| Veracyte, Inc. | Lung Nodule Genomic Marker Panel Test | $ 24,810.00 | $ 122,442.00 |
| Vermillion Inc | A novel diagnostic test for the diagnosis of early stage ovarian cnacer (OVA2) | $ 244,479.25 | |
| Vermillion Inc | A novel diagnostic test for the diagnosis of peripheral artery disease (PAD) | $ 244,479.25 | |
| Vertos Medical, Inc | Vertos mild for Lumbar Spinal Stenosis | $ 244,479.25 | |
| VIA PHARMACEUTICLALS, Inc | VIA-2291 | $ 244,479.25 | |
| ViaCyte, Inc | Cell Therapy for Diabetes | $ 244,479.25 | |
| Vical Incorporated | Allovectin-7 | $ 244,479.24 | |
| Vical Incorporated | TransVax | $ 244,479.24 | |
| Virobay Inc | Preclinical and Clinical Development of Cathepsin S inhibitor VBY-8911 | $ 244,479.25 | |
| VIROBAY, INC. | Clinical Development of Cathepsin B Inhibirot VBY-376 for Liver Fibrosis | $ 244,479.25 | |
| Virogenics Inc | A novel Immune Modulator/Adjuvant for HIV Vaccines | $ 85,080.50 | $ 16,544.50 |
| Virogenics, Inc | FIV Vectors for Treatment of Hemophilia A | $ 191,188.50 | |
| VisionCare Ophthalmic Technologies Inc | IMT Project #002 | $ 244,479.25 | |
| Vital Therapies Inc | ELAD Bioartificial Liver | $ 244,479.24 | |
| Vitalea Science Inc | A finger-prick medical diagnostic for vitamin B12 malabsorption: An early intervention tool | $ 219,682.44 | $ 24,796.80 |
| VITAPATH GENETICS, INC | SPINA BIFIDA PREVENTION ASSAY | $ 244,479.24 | |
| VitaPath Genetics, Inc. | Cleft Palate Prevention Assay | $ 244,479.24 | |
| VIVUS, INC. | Qnexa | $ 244,479.25 | |
| VM Discovery, Inc | Preclinical Development of VMD-902 for Chronic Neuropathic Pain | $ 225,743.84 | $ 18,735.40 |
| Voyage Medical, Inc. | Cardiac Ablation Under Direct Visualization | $ 244,479.25 | |
| Voyage Medical, Inc. | Direct Visualization Cardiac Catheter for Transseptal Puncture and Drug Delivery IRIS ™ | $ 244,479.25 | |
| WaferGen Biosystems Inc. | SmartChip Genetic Analysis for Molecular Identification of Disease States & Therapy Selection | $ 244,479.25 | |
| Wave 80 Biosciences, Inc. | Molecular Diagnostic Assays and Instrumentation for HIV Viral Load Measurement | $ 244,479.25 | |
| Wintherix, LLC | Wnt pathway inhibitor drug for epithelial and leukemic cancers | $ 244,479.24 | |
| Wiseman Research Initiatives LLC | SV-BR-1-GM, a Whole-Cell Vaccine to Treat Various Types of Advanced Cancer | $ 40,378.50 | $ 20,189.50 |
| XDX, Inc | XDx Lupus Molecular Diagnostics | $ 244,479.25 | |
| XDX, Inc. | XDx AlloMap: Molecular Diagnostic for Heart Transplant Acute Cellular Rejection | $ 244,479.25 | |
| Xencor Inc | Development of biosuperior antibodies with extended half-life | $ 244,479.25 | |
| XENCOR INC | Clinial development of XmAb5574 an antibody treating Chronic Lymphocytic Leukemia | $ 244,479.25 | |
| XENCOR, INC | Clinical development of XmAb2513, a therapeutic antibody treating Hodgkin Lymphoma | $ 244,479.25 | |
| XENCOR, INC. | Clinical development of XmAb5871, an antibody treating Lupus and other diseases | $ 244,479.25 | |
| XenoPort, Inc | XP21279 - A Transported Prodrug of L-Dopa for the treatment of Parkinson's Disease | $ 244,479.25 | |
| XenoPort, Inc. | Arbaclofen Placarbil, or AP - A Transported Prodrug of R-baclofen | $ 244,479.25 | |
| Xoft Inc | Electronic brachytherapy for the treatment of Gynecological Cancers | $ 244,479.25 | |
| Xoft, Inc | Electronic Brachytherapy for the Treatment of Breast Cancer | $ 244,479.25 | |
| XOMA Ltd | XOMA Monoclonal Antibody Therapeutics for the Treatment of Oncologic Diseases | $ 244,479.24 | |
| Xoma Ltd | XOMA's Heptavalent Anti-Botulinum Toxin Monoclonal Antibody Program | $ 244,479.24 | |
| XOMA Ltd | XOMA Monocional Antibody Therapeutics for the Treatment of Metabolic Diseases | $ 244,479.24 | |
| Xoma Ltd | XOMA 052, Gevokizumab, Anti-IL 1Beta, Anti-inflammatory therapeutic moncolonal anitbody | $ 244,479.24 | |
| Zacharon Pharmaceuticals, Inc | Sensi-Pro Diagnosic for the Mucopolysaccharidoses ( MPS) | $ 219,911.00 | $ 24,568.24 |
| Zacharon Pharmaceuticals, Inc | Development of ZP2571: The first inhibitor of 6-O sulfation of herparan sulfate for cancer | $ 244,479.24 | |
| Zacharon Pharmaceuticals, Inc. | Development of AP10295: A novel ganglioside inhibitor for the treatment of cancer | $ 244,479.24 | |
| Zacharon Pharmaceuticals, Inc. | ZP2345: The First inhibitor of 2-O sulfation of heparan sulfate for the Mucopolysaccharidoses | $ 181,546.50 | $ 62,932.74 |
| Zenobia Therapeutic, Inc | Discovery of inhibitors of G2019S LRRK2 kinase for the treatment of Parkinson's disease | $ 31,630.00 | |
| Zenobia Therapeutics, Inc. | Discovery of inhibitors of caspase 6 kinase for the treatment of Huntington's disease | $ 12,500.00 | |
| Zogenix Inc | DosePro | $ 244,479.25 | |
| Zogenix, Inc. | ZX002 | $ 244,479.25 | |
| ZOGENIX, INC. | Sumavel DosePro | $ 244,479.25 | |
| Zosano Pharma, Inc. | Novel PTH Microprojection System for improved treatment of severe osteoporosis | $ 244,479.25 | |
| ZYDX. Inc | Prostate Cancer Multi-Analyte Diagnostic Test | $ 46,100.00 | |
| Zyomyx,Inc | A novel CD4 point-of-care diagnostic test for HIV monitoring | $ 244,479.24 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
